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ABSTRACT 
IDENTIFICATION OF PREDOMINANT HEPATITIS C VIRUS GENOTYPE IN 
TURKISH POPULATION 
Funda ŞAR 
M.S. in Molecular Biology and Genetics 
Supervisor: Prof. Dr. Mehmet ÖZTÜRK 
July, 2001 
Hepatitis C virus (HCV) is a major cause of acute and chronic hepatitis, leading to 
cirrhosis and hepatocellular carcinoma. Approximately 170 millions of person are 
chronically infected with HCV worldwide. HCV is an enveloped positive stranded 
RNA virus with 9.5 kb genome. The error-prone replication of HCV leads to its highly 
heterogeneous nature. There are 6 main genotypes and around 70 subtypes. The 
genotypes and subtypes of HCV have different prevalence rates and geographical 
distributions. They also differ in clinical manifestations, such as response to interferon 
treatment and disease progression. The identification of genotype distribution is of 
scientific importance because of its help in understanding of epidemiology of HCV and 
the clinical implications of the genotypes. In a previous study, conducted in our 
laboratory, the predominant genotype of HCV in South and Southeast Anatolia regions 
of Turkey was determined as subtype 1b with 91% prevalence. Subtype 1a, 2a and 4 
were also present with lower prevalences, 6.3%, 1.3%, 1.3%, respectively.  The high 
prevalence rate of subtype 1b and limitations of genotyping from 5' UTR in 
discrimination between subtype 1a from subtype 1b lead to confirmation of these results 
from another region of HCV genome.  In this study, to confirm the results of the 
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previous study we sequenced part of NS5B region and constructed phylogenetic tree. 
The results of this study were in concordance with the former study, indicating the 
predominant genotype as subtype 1b in South and Southeast Anatolia regions of 
Turkey. After identification of subtype 1b as the predominant genotype, a Turkish 
HCV-1b isolate was sequenced. Cloning and the partial sequence of HCV-1b isolate 
was performed by Aslý Öztan and in this study, we obtained the complete nucleic acid 
sequence of a Turkish HCV-1b isolate. It comprises 9361 nucleotides, including 306 
nucleotides of 5' UTR, a single long open reading frame of 9033 nucleotides, and 22 
nucleotides of 3' UTR.  By sequence comparisons, we characterized the Turkish HCV-
1b isolate. 
 
Keywords: Hepatitis C Virus (HCV); genotyping; subtype 1b; NS5B; Southern 
Turkey; full length; Turkish HCV-1b isolate. 
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TÜRK TOPLUMUNDA BASKIN OLARAK GÖRÜLEN HEPATİT C VİRÜSÜ 
GENOTİPİNİN BELİRLENMESİ 
Funda ŞAR 
Moleküler Biyoloji ve Genetik Yüksek Lisans 
Tez Yöneticisi: Prof. Dr. Mehmet Öztürk 
Temmuz, 2001 
 
Akut ve kronik hepatitin en önemli nedenlerinden biri olan hepatit C virüsü 
(HCV) siroz ve karaciğer kanserine neden olmaktadır. Dünyada yaklaşık 170 milyon 
insanın HCV ile enfekte olduğu sanılmaktadır. HCV zarflı, pozitif, tek iplikli RNA 
virüsü olup, 9.5 kilobazlık bir genoma sahiptir. Hata oranı yüksek replikasyonu 
nedeniyle HCV genomu çok sayıda değişime uğramıştır. 6 genotipi ve yaklaşık 70 
subtipi bulunmaktadır. Bu genotip ve subtipler farklı coğrafi bölgelerde, farklı sıklıkta 
görülmektedir. Ayrıca genotip ve subtipler interferon tedavisine cevap ya da farklı 
hastalık seyri gibi değişik klinik özelliklere de sahip olabilirler. Genotiplerin 
dağılımının ve baskın genotipin belirlenmesi epidemiyolojik çalışmalar ve de 
genotiplerin farklı klinik özellikleri nedeniyle bilimsel önem taşımaktadır. 
Labaratuvarımızda HCV genomunun 5' UTR bölgesi kullanılarak yapılan önceki 
genotipleme çalışmasında Güney ve Güney Doğu Anadolu bölgelerindeki baskın HCV 
genotipi subtip 1b (91.1 %) olarak belirlenmiştir. Ayrıca subtip 1a (6.3%), 2a (1.3 %) 
ve gentotip 4 (1.3 %) daha düşük yüzdelerle saptanmıştır. Önceki çalışmada yüksek 
subtip 1b oranının bulunması ve 5' UTR bölgesinin subtip 1a ve subtip 1b yi birbirinden 
ayırmadaki yetersizliği nedeniyle bulunan sonuçların doğrulanması gereği doğmuş ve 
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bu çalışmada aynı örneklerin HCV genomunun NS5B bölgesi kullanılarak genotipleri 
tekrar belirlenmiştir. NS5B bölgesinin bir kısmı çoğaltılmış ve elde edilen nükleotid 
dizisi ile soy ağacı kurulmuştur. Sonuçlar bir önceki çalışmayı doğrulamış ve 
Türkiye’nin Güney ve Güney Doğu Anadolu bölgelerindeki baskın HCV genotipinin 
subtip 1b olduğu gösterilmiştir.  Bu sonucun elde edilmesinden sonra Aslı Öztan bir 
Türk hastadan HCV genomu izole etmiş ve klonlamıştır. Klonlanan izolatın nükleotid 
dizisinin belli bir bölümü elde edilmiş ve bu çalışmada tüm dizi belirlenmiştir. Türk  
HCV subtip 1b izolatı 9361 nükleotidten oluşmaktadır ve 306 nükleotid 5' UTR, 9033 
nükleotid açık okuma çerçevesi ve 22 nükleotid 3' UTR içermektedir. Türk subtip 1b 
izolatının amino asit düzeyinde diğer HCV izolatlarıyla karşılaştırılmış ve karakterize 
edilmiştir. 
 
Anahtar Sözcükler: Hepatit C virüsü; genotipleme; NS5B; Güney ve Güney Doğu 
Anadolu; subtip 1b; Türk HCV-1b izolatı; tüm genome 
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1. INTRODUCTION 
 
1.1 Epidemiology  
 
Hepatitis C is a major cause of acute hepatitis and chronic liver disease, 
including cirrhosis and liver cancer. An estimated 170 millions of persons are 
chronically infected with HCV worldwide and 3-4 million persons are newly infected 
each year (World Health Organization, 2000). 
 
Since the discovery of HCV, global characteristics of epidemiology have been 
documented, and except for the 57 countries, HCV prevalence rates are known (Table 
1.1). In developed countries the HCV prevalence rate is lower than 3%. In United 
States, 1.8% of population is infected with HCV (Alter, 1997). The HCV prevalence 
rate is in between 0.2-3% in Europe. In Turkey the prevalence of HCV is % 0.3-1.8 
(Babacan et el., 1994; Sharara et al., 1996). 
    
There are a few countries with very high HCV prevalence rate, such as Egypt, 
where 10-30% of population is infected with HCV (Arthur et al., 1997; El-Sayed et al., 
1996; Hibbs et al., 1993). The nationwide company to treat schistosomiasis infections 
by inoculation of needles in 1970s is hypothesized to be responsible for this high 
prevalence, as lower HCV prevalence among individuals born after the end of campaign 
as a preliminary evidence was observed (Angelico et al., 1997; El-Zayadi et al., 1997; 
Frank et al., 2000). As the study of HCV isolates obtained throughout Egypt did not 
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reveal similar evolutionary distance among isolates and also regional clustering, this 
hypothesis should be tested further (Ray et al., 2000). 
      
In certain countries undeveloped geographical regions show high HCV 
prevalence rate.  For example, in the Ararhiro region of Japan 45% of individuals over 
41 years of age had HCV infection (Kiyosawa et el., 1994). 
 
Table 1.1: Worldwide Hepatitis C Prevalence 
 
WHO Region Total 
Population 
(Millions) 
Hepatitis C 
Prevalence 
Infected 
Population 
(Millions) 
Number of 
countries by 
WHO Region 
where data 
not available 
Africa 
 
602 5.3 31.9 12 
America 
 
785 1.7 13.1 7 
Eastern 
Mediterranean 
466 4.6 21.3 7 
Europe 
 
858 1.03 8.9 19 
South-East 
Asia  
1500 2.15 32.3 3 
Western 
Pacific 
1600 3.9 62.2 11 
Total 
 
 
5 811 3.1 169.7 57 
 
Adapted from World Health Organization, 2000. 
 3 
1.2 Transmission 
 
Current transmission of HCV is primarily associated with parenteral exposure to 
blood through medical procedures or from needle sharing amongst intravenous drug 
users. However, the predominant mode of HCV transmission changes over time. For 
example, blood transfusion became common medical procedure only after Second 
World War, before that the use of unsterile needles were frequently followed by the 
cases of jaundice. Predominant transmission routes also differ in between or within 
countries. While in economically developed countries, mostly HCV infections are 
mostly related to drug use and also blood transfusion, in economically undeveloped 
countries traditional or folk medical procedures may lead to HCV transmission. 
 
There are several routes of HCV transmission. Primary one as mentioned above 
is the blood transfusion. HCV infection was observed in the 80% of recipients of blood 
from HCV-infected blood donors, (Esteban et al., 1991; Vrielink et al., 1995). This 
points the great importance of blood screening and development of specific and 
sensitive HCV detection methods. 
 
HCV outbreaks in the past helped for the understanding of intravenous 
administration of contaminated blood products (immunoglobulins and clotting factors) 
as a cause of HCV transmission (Power et al., 1994; Yap et al., 1994). Decontamination 
of immunoglobulins and the use of recombinant clotting factors would probably 
decrease the incidence of HCV due to transfusion of blood products. 
 4 
 
Use of contaminated needles is one of the important routes of transmission, 
which is the main risk factor for the health care workers. Only 2-8 % of needle 
exposures lead to HCV transmission (Kiyosawa et al., 1991; Ridzon et al., 1997). This 
rate depends in part on the quantity of blood transferred, the titer of the virus, and the 
depth of inoculation. Illicit use of drugs, especially by injection, accounts for the 
majority of HCV infection in many developed counties. Since 1992, at least two-thirds 
of new HCV infections in United States have been to due to drug use. Worldwide, 50-
95% of persons acknowledging drug use have HCV infection. Needle-exchange 
programs have been associated with a reduction in HCV incidence, but their use is 
restricted to certain countries (Hagedorn and Rice, 2000). 
 
Nosocomial transmissions between patients-to-patients, health care workers-to-
patients and vise versa happen rarely. In one reported case, use of the same 
colonoscope, previously used for an HCV infected patient resulted in the transmission 
of HCV (Bronowicki et al. 1997). There are several cases of HCV transmission between 
patients-to-patients after dialysis procedure (Jadoul, 2000; McElborough et al., 2001; 
Taskapan et al., 2001). HCV RNA has been detected in 10-52% of patients on 
hemodialysis. Duration and frequency of hemodialysis correlates with the risk of 
transmission (Alter, 1995; Heintges and Wands, 1997).  
 
Transplantation of organs from HCV-infected donors almost always transmits 
HCV to recipients (Pereira et al., 1991; Terrault et al., 1995). New liver is infected by 
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circulating viruses and/or by viruses possibly produced at extrahepatic sites. However, 
there are still continuing discussions about the risk factor of transplantation of other 
organs other than liver from HCV-infected individuals. 
 
Mother-to-infant (vertical) transmission of HCV has been documented with a 
rate of 0-8% (Halfon et al., 1999; Lam et al., 1993; Reinus et al., 1992; Zanetti et al., 
1995). The time of transmission is not known. Therefore, there is no way to prevent it at 
present. As the antibodies of the mother passes and persists in the child for 12 months, 
before this period, presence of HCV infection in the child should be tested with PCR. 
 
Sexual intercourse is an inefficient transmission route. Persons with multiple 
sexual partners or sex workers are in the high risk group of the sexual transmission 
(Utsumi et al., 1995; van Doornum et al., 1991). The unprotective sexual intercourse, 
long duration of relationships with HCV-infected individuals also increases the risk of 
infection. Thomas et al performed a study with sexually transmitted disease clinic 
patients (without other percutaneous risk factors) and their partners. They observed that 
sexual transmission of HCV from males to females might be more efficient than from 
females to males. The prevalence rates of heterosexual and homosexual persons are 
similar (Thomas et al., 1995).  
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1.3 Natural History and Disease Manifestations 
 
HCV infection either resolves after acute infection or establishes chronic 
infection in the majority of patients. Incubation period is in average 50 days; it may 
differ between 15-150 days (Hagedorn and Rice, 2000). In the acute phase of infection, 
liver cell injury and elevated serum alanine aminotransferase (ALT) levels are 
observed. Ten times higher ALT level was recorded approximately in 80% of HCV 
patients (Hoofnagle, 1997).  Acute infection is mild or asymptomatic in 65-75% of 
patients.  20% of patients have jaundice and 10-20% suffers from malaise, anorexia, and 
abdominal pain (Centers for Disease Control and Prevention, 1998).  Acute infection 
resolves in 2-12 weeks and this is characterized by the disappearance of HCV RNA 
from blood and return of liver enzymes to normal level (Hoofnagle and Tralka, 1997).  
 
Unfortunately, after acute infection 80-85% of patients develop chronic 
infection. Hepatitis C is the leading cause of chronic viral hepatitis in many countries 
due its ability to cause persistent infection by unidentified mechanisms.  Chronic 
infection progresses very slowly after the onset of infection with mild or nonspecific 
symptoms, including fatigue and malaise. Patients with more severe infection suffer 
from weight loss, anorexia, and abdominal pain. Serum ALT levels fluctuates in 70% of 
the patients and 30% of patients have normal levels of ALT.  After a long term infection 
20% of patients develops cirrhosis and it leads the mortality in 25% of the patients with 
cirrhosis.  It is not clear whether the remaining patients will develop cirrhosis.  Marked 
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fatigue, muscle weakness, upper intestinal hemorrhage, jaundice indicates end-stage 
liver disease in the cirrhosis patients. Once the end- stage liver disease has developed, 
the only treatment is the organ transplantation. The end-stage chronic hepatitis C is the 
major cause of liver transplantations (Detre et al., 1996). 
 
Chronic infection with hepatitis C is a major cause of liver cancer in many 
countries. 1-5% of patients with chronic infection develop hepatocellular carcinoma 
(HCC) after 20 years.  HCC is more likely to develop in paients with cirrhosis and with 
long duration of infection (Hoofnagle, 1997). 
 
HCV also causes immune-complex mediated extrahepatic diseases, namely 
essential mixed cryoglobulinemia, poryphyria cutanea torda, glomerulonephritis, 
keratoconjuctivitis sicca (Johnson et al., 1993; Khella et al., 1995; Tsukazaki et al., 
1998). 
 
Natural history studies provided varying estimates of risk progression in chronic 
hepatitis. Variations in estimations may be due to viral, host and/or environmental 
factors, and also due to difficulties in performing this type of studies (summarized in 
Table 1.2). There are three types of natural history studies to determine clinical 
outcome. Prospective studies starts at the onset of the disease and follow the progress. 
Retrospective studies are performed with patients with established liver disease. 
Nonconcurrent prospective studies involve patients that are in the course of infection 
with historically defined disease onset. All these studies indicated that hepatitis C  
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Table 1.2: Problems in Conducting an Ideal Natural History 
Study of Chronic Hepatitis C Virus  (HCV) Infection 
Difficulty in Designing 
Requirement for Study   HCV Study 
 
* Accurate determination of   * Onset of acute infection 
  disease onset and       unrecognized in >80% 
  duration       of patients and must be 
           inferred 
* Inclusion of full spectrum  * Commonly asympto- 
  of acute illness      matic; most acute 
           infections are missed 
* Inclusion of full spectrum   * Often asymtomatic 
  of chronic illness      with normal ALT 
* Construction of matched   * Matched control group 
  control group without        not possible without 
  HCV        ability to identify acute 
          onset 
* Evaluation of clinical   * Treatment of chronic 
  outcome unmodified by     HCV infection now 
  treatment       common 
* Continuous evaluation to  * Period from acute 
resolution or disease      infection to overt 
endpoints       chronic liver disease can 
   span 20-40 years 
 
*Adapted from Seeff, 1999 
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infection has a benign clinical spectrum in the first 20 years of infection and cause 
moderate mortality and morbidity. However, after 30-40 years cirrhosis, end-stage liver 
disease or HCC are likely to be observed with increasing percentage. At present, the 
clinical spectrum of each individual cannot be predicted. However, factors affecting the 
natural history can be stated as male sex, older age at infection, alcohol abuse, co-
infection with other viruses and additional factors to be discovered.  
 
1.4 Diagnosis and Treatment  
 
Presence of HCV can be determined by either serological or molecular methods. 
Serological tests detect anti HCV antibodies by utilizing the HCV antigens. Enzyme 
immunoassay (EIA) is the most commonly used test, as it is least expensive and easiest 
to use. Its sensitivity is in between 92-95%. There are three versions of this test. EIA-3 
is the currently used one with recombinant hepatitis C antigens, c22-3 (encoded by core 
region), c200 (encoded by NS4 and NS3) and NS5 (encoded by NS5). A positive EIA 
result does not show present HCV infection, but may indicate the past infection. In 
addition, a negative result does not exclude the possibility of infection, as antibodies to 
HCV may not be formed at the time of test. As a result of this, supplemental tests have 
been developed. Recombinant immunoblot assay (RIBA) with 2 recombinant antigens 
(c33c and NS5), 2 synthetic peptides (c100p and 5-1-1p) and c22p peptide is designed 
to resolve false positive EIA results. Supplemental test results reported as positive, 
negative or indeterminate. If both test results are positive, then the patient is an anti-
HCV positive person. A positive EIA test result, nor confirmed by a sequential test 
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result, person is considered uninfected. 
 
Molecular assays involve RT-PCR, branched DNA (Quantiplex HCV RNA 1.0, 
Chiron Diagnostics, Emeryville, CA) and quantitative DNA assays. The main principle 
is to detect HCV RNA using amplification techniques. HCV RNA can be detected 
within 1-2 weeks after exposure to HCV, before changes in ALT levels and 
development of anti HCV. The qualitative PCR tests are quite sensitive and detect 100-
1000 copies per ml of serum. However, they only report the absence or presence of 
HCV-RNA. The quantitative PCR and branched DNA tests tries to determine the 
number of HCV-RNA per ml of serum. 
 
There is currently no vaccine available for HCV and therefore, the acquisition of 
HCV infection cannot be prevented. Interferon-α (IFN-α) monotherapy and 
combination therapy with ribavirin are the only treatments approved by FDA.  IFN-α 
empowers the immune response by increasing the efficiency of the presentation of viral 
antigens on the surfaces of infected cells and additionally, it increases the activity of the 
cytolytic T cells. The standard regimen of the IFN-α is 3 million units of IFN given 
subcutaneously 3 times-a-week for up to 12 months. Normalized ALT levels and 
disappearance of HCV RNA from serum indicates the response to IFN which takes 
place in the 50% of the patients, the remaining suffer a relapse after the cessation of the 
therapy. Optimizations in dosing and/or chemical modification of IFN improved the 
response rate, but not the relapse rate.  In different studies it has been suggested that 
increase in the dose of IFN would decrease the resistance to IFN based on the 
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observations including production of high amounts of RNA as 300 billion copies per 
day (Neumann et al., 1998). Combination therapy with ribavirin, a guanosine analogue 
has been shown to be effective in untreated and in relapsed patients (Davis et al., 1998; 
McHutchison et al., 1998). How ribavirin acts against HCV in combination therapy is 
not known. 
 
Both IFN-α monotherapy and combination therapy has certain drawbacks. 
Interferon and ribavirin have significant side effects, IFN should be given by injection, 
and the cost of treatment is high. HCV 1b and type 4 are less responsive to treatment. 
These drawbacks lead to investigations of other possible approaches to develop drugs 
based on the molecular structure of the virus. Different points in the life cycle can be a 
potential target, such as attachment and entry into cell, early translation, protein 
processing, replication, viral assembly and export (Figure 1.1). Several drugs targeting 
the NS3, NS5B or NS4 proteins have been tried, so far no optimal drugs have been 
found. 
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Figure 1.1: Novel therapeutic strategies to block hepatitis C virus (HCV) replication. Anti-HCV 
strategies (shown in red) can be aimed at several stages of the viral life cycle, including: (a) receptor 
binding; (b) penetration and uncoating; (c) early translation of viral polyprotein; (d) viral protein 
processing by proteases, including NS2, NS3 and NS4A; (e) RNA replication; (f) glycosylation of viral 
envelope proteins; (g) activation of latent RNase L and RNA-dependent protein kinase (PKR); (h) virion 
assembly; and (i) virion release. The current therapy of choice, interferon α (IFN-α) is believed to block 
the viral life cycle at several stages, including at (g), (h) and (i). 
*Adapted from Rosen and Grecth, 1999. 
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1.5 Variability of HCV Genome 
  
 HCV is an enveloped positive strand RNA virus, with approximately 9.5 kb 
genome. Similar to flaviviruses, HCV genome encodes a large polyprotein from which 
structural (core, E1, and E2) and nonstructural (NS2, NS3, NS4A, NS4B, NS5A, and 
NS5B) proteins are processed by cellular and viral proteases (Figure 1.2). HCV has 
been classified as a member of the family Flaviviridae because of its similarity in 
genomic organization to flavivirus and pestivirus. All have same N terminal location of 
structural proteins and C terminal location of nonstructural proteins. Pestivirues, 
flaviviruses and HCV have similar hydrophobicity profile of polyprotein (Choo et al., 
1991). They also share relative location of nucleocapsid, envelope glycoprotein, 
putative protease, helicase and replicase. 
 
HCV shows a great degree of variability in different regions of its genome and 
in the whole genome, which is manifested at the level of quasispecies (within a single 
host) and of genotypes (within populations). HCV exists as highly variable isolates or 
strains. Within a single host, the isolate is found as a group of different, but closely 
related sequences, termed as quasispecies.  The isolates of HCV are classified into 
genotypes based on the sequence similarities. The isolates with more than 85% 
sequence similarity in their genome are put into same subtype. The subtypes are 
grouped into types and ones showing 77-80% similarities in nucleotide sequence belong 
the same type.  Between the types of HCV there are almost 65% sequence similarity. 
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Figure 1.2: Schematic representation of HCV genome 
 15 
Based on this threefold hierarchical system, there are six main genotypes, numbered 1 
to 6 and approximately 70 subtypes, lettered a, b, c in the order of discovery (Figure 
1.3). Recently, in Vietnam (Tokita et al., 1994), Thailand (Apichartpiyakul et al., 1994; 
Mellor et al., 1995; Tokita et al., 1995) and in Indonesia (Tokita et al., 1996) new novel 
genotypes have been identified. They are distinct from types 1 to 6, but more closely 
related to type 6 than to other genotypes (Tokita et al., 1994). These variants caused a 
problem in attempting to categorize, as they appear to be intermediate in variability 
between the type and subtype categories (Simmonds et al., 1995; Tokita et al., 1996).  
 
Figure 1.3: Phylogenetic analysis of nucleotide sequences from part of the HCV NS5B region amplified 
from samples of HCV-infected blood donors and hepatitis patients from several countries. Six main 
groups of sequence variants are found corresponding to types 1-6; each group contains a number of more 
closely related subtypes (a, b, c…). Nomenclature of types 1-5 and 6a follows the consensus proposal for 
classification of HCV. Recently discovered variants from South East Asia cluster with type 6a but are 
labeled according to the original publications. TD3/type 10a from Indonesia groups similarly with type 3 
variants. Adapted from Reesink, 1998. 
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While some genotypes of HCV, namely type 1a, 1b, 2a, 2b, 3a show worldwide 
distribution, others such a type 5a and 6a are only found in specific geographical 
regions.  In Western Europe and US hepatitis C patients infected with genotypes 1a, 1b, 
2a, 2b, 2c and 3a, each with different frequencies, through Southern and Eastern Europe 
frequency of 1b increases and it is present as the predominant genotype in Turkey 
(Abacioglu et al., 1995), which is also supported by our data.  In the Middle East and in 
certain parts of North and Central Africa type 4 predominates. As mentioned above 
genotype 5a and 6a have restricted geographical range. While type 5a is present in 
South Africa, rarely found in other countries, type 6a is present in Hong Kong, Maceu, 
Vietnam. 
 
1.6 Evolution of HCV 
 
There is no historical, archeological and palaentological record of HCV, like 
many other viruses. The analysis of the current distribution and genetic relatedness 
provide the limited evidence to construct the HCV evolutionary history. Genetic 
relatedness analysis involves the calculation of time of divergence of HCV and its 
variants by using the rate of sequence change with time.  
 
Rate of sequence change over relatively short intervals of time are provided by 
number studies of experimentally infected chimpanzees or between individuals several 
years after transmission of HCV from one to the other (Abe et al., 1992; Okamoto et al., 
1992a). Presence of HCV patients infected with same, homogenous source batch of 
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antirhesus D immunoglobulin used in 1977 in Ireland provided a good opportunity to 
calculate rate of sequence change. Sequence comparisons in the NS5 and E1 regions of 
HCV isolates from the recipients after 17-20 years later revealed the rates of sequence 
change as 4.1 and 7.1x10-1 per site per year respectively (Smith et al., 1997) with no 
evidence for variation in rate between individuals.  
 
Assuming the rate of sequence change is constant over time, time of divergence 
for the variants of same subtype can be calculated. Smith et al calculated the time of 
divergence of subtype 1b variants as approximately 60-70 years. In this study, 40 NS5 
sequence from different parts of the world Europe, US, Japan, Asia was examined and 
there was no country or region specific phylogenetic groupings, which implies that the 
initial spread of type 1b was rapid. Type 3a variants show less diversity showing shorter 
time of divergence (40 years based upon distances in NS5 region), in contrast to type 
2a-c with more diversity originating 90-150 years ago. There is no clear explanation of 
factors affecting the diversification of subtypes.  However, increase in the frequency of 
significant long distance travel between continents is thought to contribute to 
diversification of the subtypes of HCV 200-300 years ago (Reesink, 1998). 
 
The methods used in calculation of rate of sequence change are generally based 
upon the silent substitution rates, as it offers several advantages. They are not affected 
by selection of variants differing in phenotypic properties arising from amino acid 
changes.  Additionally, the functional or structural constraints of HCV proteins or 
differences in between proteins do not affect the silent substitution rates. However, 
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these methods are not helpful to calculate the time of divergences of HCV genotypes. 
Since the distances between genotypes are large, evolutionary distances approach or 
near to saturation. This leads to problems in the corrections of multiple substitutions. 
Though there are algorithms to correct them, they still lead to underestimation of true 
evolutionary distances between genotypes.  Another difficulty arises from the 
extrapolation of rate of sequence change measure over a short period of time and its use 
in the long term events. 
 
In overall, with our current knowledge it is not possible to determine a 
geographical region or temporal origin for the common ancestor of HCV genotypes.  
Nonetheless, the geographical distributions as well as antigenic and biological 
differences between HCV types are correlated with the long term endemic infection 
with no significant exchange of types between different geographical regions. 
 
1.7 The Concept of Quasispecies 
 
Analogous to the other RNA viruses, HCV circulates as heterogeneous but 
related genomes, called quasispecies (Bukh et al., 1995; Eigen 1996; Holland et al., 
1992; Martell et al., 1992). This viral population is composed of a dominant sequence 
called master sequence and a number of different sequences. Master sequence generally 
represents the consensus sequence of the population. The consensus sequence is the 
sequence resulting from combining the most common nucleotide at each position of the 
genome and is obtained by direct sequencing of PCR products or by sequence analysis 
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of at least three clones. This sequence might not represent an actual genome in the 
quasispecies, but it is useful to identify the changes that affect a representative 
proportion (> 50%) of total quasispecies population. 
 
The heterogeneity of HCV within an individual can be attributed to error prone 
RNA-dependent RNA polymerase (RdRp) of HCV, NS5B. The absence of proof 
reading activity of NS5B creates de novo mutations. Recently, HCV RNA turnover rate 
is calculated in humans as 4-7 hours and this high turnover rate leads to production of 
300 billion HCV RNA molecules per day (Lam et al., 1997; Neumann et al., 1998), 
which contributes significantly to the heterogeneity of HCV. It was hypothesized that 
the existence of HCV as quasispecies may be the basis of the mechanism for viral 
persistence. With high numbers of RNA produced per day and NS5B without 
proofreading activity would lead to production of escape mutants, therefore, HCV 
establishes chronic infection. 
 
Antibodies as a result of humoral immune response are produced to neutralize 
HCV. But neutralization does not take place as a sterilizing one because of the 
replication of minor species escaping from the antibodies, raised against master 
sequence (Kato et al., 1993; Shimizu et al., 1994; Weiner et al., 1992). Therefore the 
minor species predominates and establishes the persistent infection. Cell-mediated 
immunity may also select variants and contributed to persistence of HCV infection. 
Cell-mediated immune response recognizes more than one epitope (Koziel et al., 1992; 
Koziel, 1997). This property makes the studies to reveal the importance of cell-
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mediated immune response more difficult as it creates the need of full length genome 
analysis to identify important mutations in different regions of HCV genome.    
 
Opposite to reports supporting this hypothesis, there are also contradictory 
studies. For example, the envelope sequences from persistently infected patients 
sometimes show no significant change (Higashi et al., 1993; Kumar et al., 1993; Okada 
et al., 1992) as opposed to others, which have antibodies activities against hyper 
variability region 1 (HVR-1) in the E2 region preceding or coexisting with variants 
containing those sequences. RNAs transcribed from infectious cDNA clones from HCV 
strain H77, genotype 1a inoculated intrahepatically into chimpanzees, long term follow 
up of chronically infected chimpanzees indicated that there was no amino acid sequence 
change in the E1 and E2 proteins during the first year of study in the presence of anti-
E1 and anti-E2 antibodies (Forns et al., 1999). 
 
There are alternative mechanisms to explain HCV persistence. One of them 
involves the presence of decoy antigens. Different regions of the genome have been 
suggested to have different selective pressure. Therefore, while a region stimulates a 
strong response, mostly ineffective for clearance of virus, it also delay or suppress the 
response to other less dominant epitopes, providing the focus of immune response to 
many regions of HCV (Forns et al, 1999). 
 
In addition to its possible importance in the viral persistence, quasispecies may 
have a role in response to IFN. It was reported that greater degree of quasispecies 
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complexity is related to resistance to IFN (Farci et al., 1997). Quasispecies complexity 
may provide the selection variants with resistance to drugs. The effect of quasispecies 
to natural history of infection has not been well characterized. However, it has been 
suggested that the increase in the quasispecies complexity increases severity of the liver 
disease (Farci et al., 1997; Honda et al., 1994). To understand the effects of dynamics of 
quasispecies on disease progression, quasispecies in patients after liver transplantation 
has been examined and it was observed that orthotropic liver transplantation patients 
can either retain the major HCV variants that were present before the transplantation, or 
new quasispecies emerge. In the former case, progression of liver damage is more rapid 
than the latter case with slower course of infection. This data suggest that some HCV 
strains might have more pathogenicity. There should be further studies to establish the 
role of quasispecies in pathogenicity of HCV and outcome of HCV-caused liver 
disease.  
 
1.8 Clinical Significance of HCV Genotypes 
 
Most of nucleotide sequence differences have been thought to accumulate 
through evolutionary drift and they are expected to have neutral effect. However, the 
heterogeneity of HCV might have biological importance (Simmonds, 1995). 
 
Most positive strand RNA viruses have variants similar or more divergent than 
major genotypes of HCV and variants have similar course of infection. However, 
Pestiviruses, closely related to HCV have 3 types of variants differing in host range,  
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method of transmission and type of disease. This suggests the HCV genotypes might 
have biological differences, which might have clinical importance. 
 
Unavailability of cell culture system to propagate of HCV and to study 
differences in cytopathic properties as well as neutralization of HCV led to use of 
nucleotide sequence comparisons and genotyping as the main techniques for 
characterizing different variants of HCV.  
 
Several studies have been performed to investigate the clinical significance of 
HCV genotypes. The relation of HCV genotype with response to IFN, natural course of 
infection, outcome after transplantation, diagnosis of HCV antibodies has been 
suggested and summarized below: 
 
1.8.1 Molecular Epidemiology and Transmission 
 
Genotyping is of scientific importance in characterizing HCV, in understanding 
its evolution and natural history and also in tracing the routes of transmission in 
epidemiological studies. HCV genotyping was previously used in suspected cases of 
mother-to-infant and inter spouse tranmission (Akahane et al., 1994; Ohto et al., 1994). 
Ohto et al (1994) determined that in 6 out of 7 families studied, the genotypes of mother 
and infant were the same, indication of vertical transmission. More sensitive 
determination of transmission is provided by the sequence analysis.  The HCV isolates 
from recipient and suspected source of the infection are sequenced and their relatedness 
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provides the evidence for the transmission.  
 
1.8.2 Diagnosis 
 
One major concern related with the hepatitis C infection is to prevent the new 
cases of infection. Therefore, the diagnosis of HCV is very important. ELISA is the 
routinely used technique for diagnosis and most ELISA techniques detect the presence 
of anti-HCV antibodies in individuals by utilizing recombinant proteins derived from 
only one genotype (mainly subtype 1a). The reported antigenic variation between 
genotypes has raised a question about the effectiveness of these tests in determination 
hepatitis C patients infected with other variants of HCV.  
 
First and second generation HCV antibody tests were found to less sensitive for 
detection of type 2 and type 3 than type 1 infections (Harrison and Zuckerman, 1997). 
The reduction in reactivity for type 4 infections is 40% and it is 35 % for type 6 
infections (McOmish et al., 1993). Dhaliwal et al examined the sensitivity of third 
generation ELISA assay and found approximately 5 fold reduction in reactivity of type 
2 and type 3 samples compared to that of type 1 samples (Dhaliwal et al., 1996). 
Genotype-specific sensitivity of all three generation assays may lead to reduction in the 
number of patients that can be determined if they are infected with genotypes other than 
type1 and the amount of false-negative results due to this inefficiency has not been 
calculated.  
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1.8.3 Interferon Treatment 
    
Interferon-α (IFN-α) is the only approved treatment for hepatitis C infection. 
However, the response rate to therapy is only ~50%. Host factors like age, histology 
and viral factors such as viremia, and genotype have been suggested as the predictors of 
sustained response to IFN-α, among which genotype, viremia and histology are 
independently associated with the outcome of therapy (Chemello et al., 1994; Martinot-
Peignoux et al., 1995). The independent effects of viral factors to response suggested 
the presence of intrinsic property of HCV to confer the sensitivity to IFN-α. Among the 
analyzed genotypes, 1a, 1b, 3a, 2 and 4, genotype 1b and 4 have been associated with 
low response rate, while 1a, 3a, 2 have been associated with higher response rate 
(Chemello et al., 1994; Tsubota et al., 1994; Yoshioka et al., 1992). 
 
  As the subtype 1b is highly prevalent in many countries. It has been the focus of 
attention. Enomoto et al by comparing full length genome sequences identified a 39 
amino acid long region (2209-2248) in carboxy terminus of N55A, which is associated 
with sensitivity to interferon and referred as interferon sensitivity determining region 
(ISDR) (Enomoto et al., 1996). They found that the IFN-α resistant strains had same 
sequences with HCV- 1b prototype strains in the ISDR region (HCV- J, HC- J4 and 
HCV- JTa). Mutations in this region lead the sensitivity to IFN. For example, between 
ISDR region of type 2 and that of HCV- 1b prototypes there are 14 amino acid 
differences and deletion of 4 amino acids (Kurosaki et al., 1997). Findings of several 
studies are in parallel with Enomoto`s study (Chayama et al., 1997a; Halfon et al., 
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2000), however, there are contradictory reports as well (Hofgartner et al., 1997; Khorsi 
et al., 1997; Squadrito et al., 1997). Whether, the presence wild type ISDR sequence is 
the basis of interferon sensitivity should studied further. 
 
The analysis of genotype and its effects on response to IFN are limited to 
genotypes 1a, 1b, 2, 3a, 4. Whether other genotypes such as 5 or 6 or subtypes confer 
resistance to IFN remains to be elucidated. 
 
1.8.4 Disease Progression 
  
The relation between genotype of HCV and progression of liver diseases has 
been subject to investigation. Most of the studies have the form of cross-sectional 
studies in which the frequency of infection due to different genotypes are in comparison 
with different stages or outcomes of the disease, such as cirrhosis and HCC. 
 
Several studies indicated the association with certain genotypes and different 
histopathological manifestations. Several studies showed that subtype 1b infections 
proceed much faster to severe forms of chronic hepatitis, cirrhosis (Booth et al., 1995; 
Kasahara et al., 1995; Watson et al., 1996), and hepatocellular carcinoma (Bruno et al., 
1997; Silini et al., 1996; Zein et al., 1996). However, there are also reports failed to 
show the association between subtype 1b infections and faster progression into cirrhosis 
(Dusheiko et al., 1994; Mita et al., 1994) or HCC (Lee et al., 1996; Yotsuyanagi et al., 
1995)  
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  To date, type 1 and type 2 infections have been examined to identify the 
possible effect of genotypes on disease progression. Although in subtype 1a and type 2 
infections there have been observed cirrhosis and HCC, both cases have been associated 
with less severe states of disease compared with subtype 1b infections. In Middle East 
and Europe, type 4 infections are associated with high frequencies of cirrhosis and 
HCC. However, in Central Africa it has a benign course of disease. Unfortunately, there 
are no studies characterizing infections of other subtypes or types. 
 
1.8.5 Vaccine Development 
 
There is no vaccine available for hepatitis C virus. Development of a suitable 
HCV vaccine has been impaired by the ability of HCV to establish persistent infection 
in the presence of an immune response, and by the heterogeneous nature of HCV with 6 
main genotypes and 70 subtypes. It has been suggested that the sequence heterogeneity 
may lead to differences in antigenic properties of epitopes of the HCV. It was shown 
that antibodies to type 1 derived NS4 and NS3 proteins do not recognize the non-type 1 
derived NS4 and NS3 proteins. 
    
Presence of genotype-specific antibodies pointed out the importance of 
development of a multivalent HCV vaccine. Therefore, to improve the vaccine potency 
for the different regions of the world with different genotype prevalence rates, there 
should be immunogens from each major genotypes or cross-reactive HCV epitopes. The 
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future of the battle to protect new cases of infection HCV will depend on knowledge of 
subtypes of HCV in different countries, regions and risk group under study. With high 
prevalence rate and worse clinical spectrum subtype 1b is one of major consideration.  
 
1.9 Genotyping Methods  
 
Several genotyping methods have been developed to genotype HCV rapidly and 
specifically. The important point in the development of the method is the target 
genomic region to be analyzed. It should represent the diversity of entire genome. The 
region should be variable enough to distinguish between types and subtypes, but also it 
should be conserved enough to develop sensitive and specific primers or probes. For 
genotyping studies, 5' UTR, E1, core and NS5B regions have been used and 
methodologies include type-specific PCR, RFLP, InnoLipa probe assay, direct 
sequencing and subsequent phylogenetic analysis of subgenomic regions. The 
concordance in HCV genotype assignment among these approaches has been 
questioned. In a previous study, 6 different genotyping methods were compared and 
overall concordance have been found as 93%. Therefore, the choice of method depends 
on the aim and nature of the study, advantages and disadvantages of methods, size of 
the sample population and cost-effectiveness.  
 
1.9.1 Type-Specific PCR 
 
Okamoto and his co-workers established a system for genotyping of subtypes 
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 1a, 1b, 2a and 2b in which a part of core region was amplified with a 
universal set of primers, followed by a nested amplification with subtype-specific 
primers (Okamoto et al., 1992b). The amplified PCR products with different lengths 
were analyzed by agarose gel electrophoresis. The genotypes are deduced from the 
length of fragments. New variations of this method from both this region and NS5B 
region have been developed to increase genotyping of more types or subtypes 
(Chayama et al., 1993; Ohno et al., 1997; Okamoto et al., 1993). 
 
1.9.2 Restriction Fragment Length Polymorphism 
 
RFLP analysis of HCV genome for genotyping was initially reported by Nokao 
and his co-workers (Nakao et al., 1991). Subtype or type-specific restriction enzyme 
recognition sites present in amplified PCR products are utilized to cut PCR fragments 
with different restriction endonucleases. Electrophoresis profiles of these are used to 
identify the genotype of the sequence. In the RFLP analysis, 5’UTR or NS5B region has 
been used widely with variations.  
 
1.9.3 Reverse Hybridization Techniques 
 
1.9.3.1 The Line Probe Assay (LIPA)  
 
The line probe assay (INNOLIPA HCV II, Innogenetics, Zwijndrecht, Belgium) 
is a reverse hybridization assay and utilizes the variations found in the 5’UTR of the 
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different HCV genotypes. In this technique, probes of 16 nucleotides are attached to 
nitrocellulose membrane with a poly(T) tail added by terminal deoxynucleotidyl 
transferase. Biotin labeled PCR products obtained from 5’UTR are then reversely 
hybridized to probes on the strip, allowing identification of genotype, 1a, 1b, 2a-2c, 3a-
3c, 4a-4h, 5a and 6a.  
 
1.9.3.2 DNA Enzyme Immunoassay (DEIA) 
 
The principle of DEIA is same with the InnoLipa Assay; however, it is based on 
the genotype-specific probes deduced from core region. The DEIA Kit (GEN-ETI-K 
DEIA Kit; Sorin, Soluggia, Italy) allows the identification of subtype 1a, 1b, 2a, 2b, 2c, 
3a, 4, and 5. Overall agreement between LIPA-I and DEIA is 87.5%. 
 
1.9.4 Direct Sequencing 
 
In theory, the most accurate method for HCV genotyping is the sequencing of 
whole genome and phylogenetic tree construction. However, in practice this method is 
not appropriate and feasible in genotyping large numbers of samples as full-length 
genome sequencing is too laborious and expensive. Hence, subgenomic regions 
representative of whole genome have been investigated. To this date, phylogenetic 
analysis E1, NS5B, and 5’UTR sequences correlated with whole genome based 
phylogenetic analysis suggesting the equivalence of sequence relationships between 
HCV genotypes in different regions of genome. This finding formed the basis of the 
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proposal by Simmonds et al. that a new HCV genotype should be assigned only if 
phylogenetic analysis of at least two genomic regions showed a distinct phylogenetic 
branch (Simmonds et al., 1994). 5’UTR region is the most conserved region of HCV 
genome. Therefore, it may have identical sequence in different subtypes but contains 
variations aiding determination of 6 genotypes and some subtypes.  
 
Amplification of NS5B, core, E1 regions, followed by sequence comparison and 
phylogenetic tree construction for confirmation, is currently considered  “gold-
standard” for the assignment of HCV genotypes. However, there are limitations of this 
method. Amplification of some genomic regions may not be efficient. In this case, use 
of different sets of primers would be needed, which may lead to the selection of certain 
genotypes or quasispecies. In a large-scale genotyping study, mixed infections would 
not be identified. In these studies, the cost of the study and labor-intensive nature of this 
technique also puts boundaries to its usage.  
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1.10 AIM OF THE STUDY  
  
Due to heterogeneous nature, there exist 6 main genotypes and around 70 
subtypes of HCV. The prevalences of genotypes and subtypes differ between many 
countries or within countries as well. The determination of genotype distribution is 
important for molecular epidemiology studies to understand origin and pattern of spread 
of HCV throughout the population. The clinical importance of genotyping is due to 
effect of genotypes in diagnosis, disease progression and treatment. Therefore, 
determination of genotypes in selected population would be helpful to design the 
prevention policy for hepatitis infection accordingly. Up to this date, there is only one 
reported genotyping study in Turkey (Abacýoglu et al., 1995) and it showed that the 
predominant genotype is subtype 1b. An initial study conducted in our laboratory by 
sequencing and phylogenetic analysis of part of 5UTR region also indicated subtype 1b 
as the predominant genotype (Yýldýz et al., unpublished data). The high prevalence rate 
of HCV-1b infection and limitations of these techniques created the need of 
confirmation the previous results. In this study, we determined the genotypes of 
infected patients in Turkey.  
 
The aim of this study was to confirm HCV genotyping through the analysis of a 
part of NS5B region of HCV. In addition, we aimed to finish whole genome sequencing 
of a Turkish HCV-1b isolate, as the predominant genotype of Turkish patient. 
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 2. MATERIALS AND METHODS 
 
2.1 MATERIALS 
 
2.1.1 Chemicals and Enzymes 
 
All enzymes or reagents were purchased from the sources below: 
 
Material    Manufacturer 
 
Taq Polymerase   MBI Fermentas 
 
dNTPs     MBI Fermentas              
 
100bp DNA Marker   MBI Fermentas 
 
Gene ruler DNA Ladder  MBI Fermentas 
 
Nucleotide Removal Kit  Qiagen 
 
Revert Aid First Strand                     
cDNA Synthesis Kit   MBI Fermentas 
 
Viral RNA Isolation Kit  Qiagen 
 
Big Dye Cycle Sequencing Kit Perkin Elmer 
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2.1.2 Equipments 
 
 The list of equipments used and their manufacturers are given below: 
 
Equipment      Manufacturer 
 
Automatic Pipettes 
 
P10       Gilson 
P20       Eppendorf 
P200       Eppendorf 
P1000       Eppendorf 
 
GeneAmp PCR System 9600 and 2400  Perkin Elmer 
 
Gel Tanks 
 
Horizontal Minicell     E-C Apparatus 
Horizontal Midicell     E-C Apparatus   
 
pH Meter      E-C Apparatus 
 
Spectrophotometer DU 640    Beckman 
 
Power Supply PAC 300    BioRad 
 
UV Transilluminator     BioRad Gel Doc 2000 
 
ABI Prism 377 Automated DNA Sequencer   Perkin Elmer 
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2.1.3 Plastic Disposables 
 
The list of plastic disposables used and their manufacturers are listed below: 
 
Disposables      Manufacturer 
 
Microcentrifuge Tubes    Costar 
 
0.2 µl 
1.5 µl 
2.0 µl 
 
Test Tubes       Costar      
 
15 ml 
50 ml 
 
Micropipette Tips     Costar 
 
Micropipette Filter Tips    Greiner 
 
 
2.1.4 Solutions 
 
2.1.4.1 Solutions for Agarose Gel Electrophoresis 
 
EDTA      0.5 M (stock solution), pH 8.0  
 
1X TAE     40 mM Tris-Acetate, 1mM EDTA (pH 8.0) 
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1X gel Loading Buffer 0.25% bromophenol blue, 0.25% xylene 
cyanol, 50% glycerol, 1mM EDTA 
 
EtBr      10 mg/ml in water (stock solution) 
                                          30 ng/ml (working solution) 
 
2.1.4.2 Solutions for RNA Extraction 
 
Guanidium Thiocyanate  4M, prepared with RNase free ddH2O and 
stored at 4°C 
 
N-Laurylsarosine 0.5%, prepared with RNase free ddH2O 
and stored at 4°C 
 
Sodium Acetate 25 mM (pH 7.0), prepared with RNase free 
ddH2O and stored at 4°C 
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2.2 METHODS 
  
2.2.1 Patients 
 
Sera from 150 Turkish anti HCV positive patients from the Gastroenterology 
Department of Çukurova University in Turkey was collected and stored at –70 °C until 
use. For ethical considerations, the samples were handled under code: i.e., we dealt with 
samples designated with numbers. 
 
2.2.2 Viral RNA Extraction and cDNA Synthesis 
 
Total RNA isolation was performed by guanidium thiocyanate method (Ausubel 
et al., 1987) with minor modifications.  
 
RNA extracted from 300µl serum with freshly prepared lysis buffer, composed 
of guanidine-HSCN solution, mercaptoethanol and carrier RNA (1µg/ml). Recovery of 
RNA was provided through isopropanol precipitation. Recovered RNA was 
resuspended in 10µl DEPC-ddH2O and incubated at 95°C for 3 minutes to denature the 
secondary structure. Extracted RNAs are either stored at -70°C or used in cDNA 
synthesis. 
 
First strand cDNA was synthesized by First Strand cDNA Synthesis Kit (MBI 
Fermentas, Catalogue # K1612). cDNA synthesis was performed on 11µl resuspended  
 37 
 
RNA in a 20 µl reaction volume by using 0.2 µg of random primer, 40 unit of M-MuLV 
Reverse Transcriptase, 20 unit of Ribonuclease Inhibitor and 1mM (each) 
deoxyribonucleotide at 37°C for 1 hr. 
 
2.2.3 Oligonucleotide Synthesis 
 
A single primer pair (Enomoto et al., 1990) was used to amplify NS5B region of 
HCV isolates from different patients. Sequences of the primers are given in Table 2.1. 
In the NS5B reverse primer, there is T›A transversion at the 9th nucleotide.  
 
Oligonucleotides, used in PCR and in sequencing, were either synthesized in our 
department using Oligo 1000M DNA Synthesizer (Beckman) or obtained from 
IONTEK (Bursa, Turkey). The concentrations of the oligonucleotides were determined 
by using oligodeoxynucleotide quantification option of the spectrophotometer.  
 
Table 2.1: PCR and Sequencing Primers 
 
Primer  Position of   Sequence (5'›3') 
5' base*  
NS5B Forward 7904  TGGGGATCCCGTATGATACCCGCTGCTTTGA 
NS5B Reverse 8304  GGCGGAATACCTGGTCATAGCCTCCGTGAA 
  
 
*Position of 5' base relative to HCV genomic sequence in Choo et al., 1991         
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2.2.4 Polymerase Chain Reaction 
 
NS5B region of the HCV genome was used for genotyping of HCV isolates 
from Turkey.  To amplify DNA fragments from NS5B region single primer pair 
(Enomoto et al., 1990), thought to be highly conserved amongst different variants of 
HCV was used.  
 
Due to low viral titer of HCV, two-step PCR with the same primer was 
established. By two step PCR, a 400 bp DNA fragment covering region 7904 to 8304 
(Position of 5` base relative to HCV genomic sequence in Choo et al., 1991) was 
amplified with Thermus aquaticus Polymerase (MBI Fermentas, Catalogue # EPO401). 
To avoid risk of contamination, different places of the laboratory were assigned as pre 
and post PCR areas for each step of the two step PCR. Each area contained different 
reagents, disposables and equipment. 
 
For optimization studies, an NS5B DNA fragment, cloned from a Turkish HCV 
1b isolate (by Aslý Öztan in our department) was used. Several concentrations of DNA 
template (NS5B clone), dNTPs, primer and MgCl2 were tested.  Optimized PCR 
conditions are present in Table 2.2. 
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Table 2.2: Optimized PCR Conditions 
 
Fragment 1st PCR Mix    2nd PCR Mix   PCR  
 
 NS5B  ¼ of total cDNA  4/50 of the PCR   94 °C 4’ 
  50 pmol/µl primer  product   94 °C 40”       
1X Taq Polymerase Buffer 50 pmol/µl primer  58 °C 40”   
 60µM dNTP   1X Taq Polymerase Buffer 72 °C 40” 
  2.5 units of Taq Polymerase 60µM dNTP   72 °C 10’  
       2.5 units of Taq Polymerase 
 
* Each PCR step was performed as 30 cycles.  
 
 
2.2.5 Agarose Gel Electrophoresis of DNA Fragments 
 
DNA fragments were separated by gel electrophoresis using agarose at 
concentrations of 1.7% w/v in 1x TAE (Maniatis et al., 1982). 0.2-0.4 µg EtBr per ml of 
the gel was used to visualize the DNA. DNA samples were loaded into the wells with 
1X loading buffer. Electrophoresis was performed by running the gel for 1 hour at 100 
V.  PCR products were visualized by UV illuminometer at 302 nm and the gels were 
photographed by Sony Video Graphic Printer UP-890 CE. The length of DNA 
fragments was determined by comparison of NS5B fragments with molecular weight 
standards, that had been loaded and run on the same agarose gel. DNA weight markers 
used in this study were PhiX174/HinfI marker (MBI Fermentas, Catalogue # 
SMO0261) and 100bp DNA ladder (MBI Fermentas, Catalogue # SMO242). 
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2.2.6 Automated DNA Sequencing 
 
The amplified DNA fragments were processed with Nucleotide Removal Kit 
(Quiagen, Catalogue # 28304) to remove excess dNTPs, MgCl2, etc. After purification 
concentrations of the PCR products was determined by comparison with known weight 
standards through utilizing agarose gel electrophoresis. The PCR products having 20-
100 ng/µl concentrations were sequenced with the same primer pair (Table 2.1) by ABI 
Prism 377 DNA Sequencer at Molecular Biology and Genetics Department in Bilkent 
University by Tülay Arayýcý.  For sequencing reactions, Big DyeTM Terminator Cycle 
Sequencing Ready Reaction Kit (ABI Prism, Catalogue # 4303152) was used. Cycle 
sequencing employs a thermostable DNA polymerase and dideoxynucleotides are used 
in a polymerization reaction to create a nested set of DNA fragments with 
dideoxynucleotides at the 3' terminus of each fragment. As each of the four dideoxies 
labeled with a different color fluorescent dye, the reaction can be performed in single 
tube and the sequence can be determined easily. Electropherograms of each sample 
were analyzed and ambiguities in the sequence data are solved by comparison of the 
results of both forward and reverse primers as well as by comparison with the HCV 
sequences in the NCBI database. Genotypes of each sample were determined after 
sequence analysis.  
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2.2.7 Analysis of DNA Sequences and Genotype Determination 
 
Multalin program (http://npsa-pbil.ibcp.fr) was used to perform the multiple 
sequence alignment of all available NS5B sequences at NCBI Taxonomy database 
(http://www.ncbi.nlm.nih.gov/Taxonomy/taxonomyhome.html) to reveal the subtype-specific 
consensus sequences of 1a, 1b, 1c, 2a, 2b, 2c, 3a, 4a, 4d, 4f, 4h, 5a, 6a (given in 
Appendix B). Consensus sequence represents an average sequence for each HCV group. 
The obtained NS5B sequences were aligned with subtype-specific consensus sequences 
by Clustal W program (http://workbench.sdsc.edu). The alignment of the sequences was 
used to construct the phylogenetic tree to determine the genotypes of the samples. 
Phylogenetic tree was inferred by using Drawtree program. The tree can be viewed 
under the account with “hcv” username and “hcv” password 
(http://workbench.sdsc.edu). Genotype of the sample is determined as the genotype of 
consensus sequence, if they are present under same phylogenetic branch. 
 
2.2.8 Characterization of HCV-1b Isolate from Turkey 
 
Full length HCV isolate from a female, 59 years old, Turkish patient was 
amplified in 7 overlapping PCR fragments (Figure 2.1) and cloned into pGem-T Easy 
Vector System (Aslý Öztan, M.S. Thesis, MBG, Bilkent).  The automated DNA 
sequencing of the inserts were performed with sequencing primers by ABI Prism 310 
Sequencer.  
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The obtained nucleic acid sequence was translated into protein sequence by 
Translator program (http://www.expasy.ch/tools/dna.html). Inferred amino acid sequence 
of Turkish HCV-1b isolate were aligned with protein sequences of other HCV isolates 
in NCBI database (http//:www.ncbi.nlm.nih.gov) by Clustal W program to identify the 
differences in amino acid sequences, that may be specific to the Turkish isolate. 
Alignment is present at the same URL mentioned above. At each position, we compared 
the amino acid sequences and we defined an amino acid difference if and only if none 
of the amino acid sequence agree with that of Turkish HCV-1b isolate. 
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Figure 2.1: Amplification Strategy of HCV Genome 
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3. RESULTS 
 
3.1 Review of the Previous Study 
 
In our laboratory, sequencing of 5' UTR region and subsequent phylogenetic 
analysis was utilized to assign the genotypes of HCV isolates obtained from 123 anti 
HCV positive patients living in Southern Anatolia in Turkey (Yýldýz et al., unpublished 
data). In 115 (93.5%) patients, HCV RNA was detected by RT-PCR of 5' UTR.  In eight 
(6.5%) patients, HCV RNA could not be detected and this is confirmed by analysis of 
different aliquots of same serum samples of the patients. The clinical features of 
patients with positive and negative HCV RNA are present in the Table 3.1. The results 
of genotyping from 5' UTR showed that the predominant genotype in Turkey is subtype 
1b (91.1%). Subtype 1a (6.3%), subtype 2a (1.3%) and genotype 4 (1.3%) are also 
present with lower prevalence (Table 3.2).  The 5' UTR region is a highly conserved 
region, subtype 1a and subtype 1b is not efficiently discriminated from this region. 
Therefore, it was important to confirm the previous study by analyzing a different 
region of HCV in selected samples. 
 
In this study, we analyzed the HCV isolates from the same patients by 
sequencing of part of the NS5B of the HCV genome after PCR amplification, as a 
means of validating results obtained with the 5' UTR.   
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Table 3.1: Clinical features of 123 HCV antibody-positive patients with or without 
HCV RNA 
 HCV-POSITIVE  HCV-NEGATIVE 
Number of cases 116/124  (93.5  %) 8/124  (6.5 %) 
Age (yrs±SD) 48.3 ± 13.3 
(n = 114) 
45.9 ± 13.5 
(n = 7) 
Sex (M/F) 46/70 2/5 
Hbs Ag positive 4/110 (3.6 %) 1/7 (14.3 %) 
Anti-HBs Ab positive 47/106 (44.3 %) 3/6 (50.0 %) 
Anti-HBc Ab-positive 43/105 (40.9 %) 3/6 (50.0 %) 
Elevated ALT (≥ 40 IU) 70/112 (62.5 %) 2/7 (28.5 %) 
Elevated AST (≥ 40 IU) 74/112 (66.1  %) 2/7 (28.5 %) 
Normal liver histology 7/114 (6.1  %) 3/8 (37.5 %) 
Chronic hepatitis*  77/114 (67.5 %) 5/8 (62.5 %) 
Cirrhosis**  26/114 (22.8 %) 0/8 (0.0 %) 
Other***  4/114 (3.5 %) 0/8 (0.0  %) 
 
*Severe chronic hepatitis (n=43), mild chronic hepatitis (n=28), chronic hepatitis (n=7), 
severe chronic active hepatitis (n=2), chronic active hepatitis (n=1), chronic persistant 
hepatitis (n=1). 
**Cirrhosis (n=11), active cirrhosis (n=8), macronodular cirrhosis (n=3), macro and 
micronodular cirrhosis (n=3) 
***Non specific reactive hepatitis (n=1), severe hepatitis (n=1), single cell necrosis 
(n=1), periportal steatosis (n=1). 
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Table 3.2: HCV genotypes in Turkish Patients 
 Genotype 1a Genotype 1b Genotype 2a Genotype 4 
Number of cases 5/79  
(6.3 %) 
72/79 
(91.1%) 
1/79  
(1.3 %) 
1/79  
(1.3 %) 
Age (yrs; mean ± S.D.) 49.75 ± 3.6 
(n=4) 
48.7 ± 13.5 
(n=71) 
52 39 
Sex (M/F) 2/3 24/47 1/0 0/1 
Elevated ALT (≥ 40 IU) 2/4  
(50.0 %) 
44/69  
(63.8 %) 
0/1  
(0.0 %) 
1/1  
(100.0 %) 
Elevated AST (≥ 40 IU) 1/4 
(25.0 %) 
47/69 
68.1 %) 
1/1 
(100.0 %) 
1/1 
(100.0 %) 
Normal liver histology 0/5  
(0.0 %)  
3/71  
(4.2 %) 
0/1  
(0.0 %) 
0/1  
(0.0 %) 
Chronic hepatitis 3/5 
(60.0 %) 
48/71 
(67.6 %) 
1/1 
(100.0 %) 
1/1 
(100.0 %) 
Cirrhosis 2/5 
(40.0 %) 
17/71 
(23.9 %) 
0/1 
(0.0 %) 
0/1 
(0.0 %) 
Other 0/5 
(0.0%) 
3/71 
(4.2 %) 
0/1 
(0.0 %) 
0/1 
(0.0 %) 
 
 
3.2 Partial Amplification of NS5B Region 
 
400 bp fragment of NS5B region of HCV isolates was amplified by two-step 
two step PCR with same primer pair (Table 2.1). Due to low amount of HCV template, 
the yield of PCR amplification was low. Therefore, two step PCR was used to increase 
the yield. To avoid contamination during amplification procedure, first round of PCR 
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(designated as PCR1) and second round of PCR (designated as PCR2) was performed in 
different areas of laboratory. The pre and post PCR areas of each step were also 
different and each area contained its own settings, pipettes, pipette tips, etc. To control 
the presence of contamination in the PCR1 two negative controls were included, ddH2O 
and cDNA of the patients, in which HCV RNA could not be detected previously by 
Esra Yýldýz. In the PCR2, addition to two negative controls one more negative control, 
ddH2O was added to eliminate the risk of contamination coming from the second round 
of PCR. 
 
The amount of cDNAs was not suitable to optimize the PCR conditions it was 
not possible to test several dNTP, MgCl2, primer or template concentrations by using 
same cDNA as a template. Therefore, optimized PCR conditions were established 
through utilizing the NS5B clone.  
 
In the Figure 3.1, Figure 3.3, Figure 3.5 agarose gel electrophoresis profiles of 
NS5B PCR products after the first round of PCR can be seen. In the Figure 3.2, Figure 
3.4, Figure 3.6 that of NS5B PCR products after the second round of PCR can be 
observed. 
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Figure 3.1: Agarose gel electrophoresis of PCR1 products.  Lane 1: 
PhiX174/HinfI marker (MBI), Lane 2: Sample 8, Lane 3: Sample 8, Lane 4: 
Sample 24, Lane 5: Sample 40, Lane 6: Sample 67, Lane 7: Sample 20, Lane 
8: Sample 76, Lane 9: Sample 80, Lane 10: Sample 85, Lane 11: Sample 94, 
Lane 12: Sample 114, Lane 13: Sample 126, Lane 14: NC*, Lane 15: NC* 
*NC: Negative control 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Agarose gel electrophoresis of PCR2 products.  Lane 1: 
PhiX174/HinfI marker (MBI), Lane 2: Sample 8, Lane 3: Sample 24, Lane 4: 
Sample 40, Lane 5: Sample 67 Lane 6: Sample 20, Lane 7: Sample 76, Lane 
8: Sample 80, Lane 9: Sample 85, Lane 10: Sample 94, Lane 11: Sample 114, 
Lane 12: Sample 126, Lane 13: NC*, Lane 14: NC* 
 
 
 
 
             1        2       3        4        5        6        7      8      9      10      11     12     13      14       
 
  1       2       3       4       5        6      7       8       9     10     11    12     13      14    15 
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Figure 3.3: Agarose gel electrophoresis of PCR1 products.  Lane 1: 
PhiX174/HinfI marker (MBI), Lane 2: NC*, Lane 3: NC*, Lane 4: Sample 216, 
Lane 5: Sample 215, Lane 6: Sample 214, Lane 7: Sample 213, Lane 8: Sample 
212, Lane 9: Sample 211, Lane 10: Sample 132, Lane 11: Sample 131, Lane 12: 
Sample 87, Lane 13: Sample 88, Lane 14: Sample 73, Lane 15: 68, Lane 16: 
Sample 72, Lane 17: Sample 66, Lane 18: Sample 36 
*NC: Negative control 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Agarose gel electrophoresis of PCR2 products.  Lane 1: 
PhiX174/HinfI marker (MBI), Lane 2: NC*, Lane 3: NC*, Lane 4: NC*, Lane 
5: Sample 216, Lane 6: Sample 215, Lane 7: Sample 214, Lane 8: Sample 213, 
Lane 9: Sample 212, Lane 10: Sample 211, Lane 11: Sample 132, Lane 12: 
Sample 131, Lane 13: Sample 88, Lane 14: 87, Lane 15: 73, Lane 16: 72, Lane 
17: Sample 68, Lane 18: Sample 66, Lane 19: Sample 36 
 1    2     3     4     5      6     7     8     9   10   11   12    13   14   15   16    17   18  
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Figure 3.5: Agarose gel electrophoresis of 
PCR1 products.  Lane 1: 100bp DNA ladder 
(MBI), Lane 2: Sample 62, Lane 3: Sample 
62, Lane 4: Sample 81, Lane 5: Sample 89, 
Lane 6: Sample 144, Lane 7: NC*, Lane 8: 
NC* 
*NC: Negative control 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Agarose gel electrophoresis of PCR2 products.  Lane 1: 100bp 
DNA ladder (MBI), Lane 2: NC*, Lane 3: NC*, Lane 4: Sample 69, Lane 5: 
Sample 69, Lane 6: Sample 69, Lane 7: Sample 144, Lane 8: Sample 144, 
Lane 9: Sample 81, Lane 10: Sample 81, Lane 11: Sample 78, Lane 12: 
Sample 78, Lane 12: Sample 78 
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Table 3.3: Semi-quantitative representation of PCR Products 
 
Figure 3.1 and Figure 3.2 
Sample Number First Step PCR Second Step PCR 
8 + ++ 
20 - - 
24 - - 
40 - ++ 
67 - - 
76 + ++ 
80 - - 
85 - + 
94 - + 
114 - + 
Figure 3.3 and Figure 3.4 
Sample Number First Step PCR Second Step PCR 
36 - - 
66 - - 
68 + +++ 
72 - - 
73 - - 
87 + +++ 
88 - - 
131 - ++ 
132 - - 
211 - + 
212 - + 
213 - + 
214 - - 
215 + ++ 
216 - + 
Figure 3.5 and Figure 3.6 
Sample Number First Step PCR Second Step PCR 
62 - - 
81 + +++ 
89 - - 
144 + +++ 
 
 
 
 
 
 52 
 
The expected size of the PCR product is 400 bp. This was confirmed by 
comparison of the observed DNA band with the size marker in all of the previous 
figures. PCR mixture did not contain contaminating DNA, because there was no DNA 
band in the negative control samples. 
 
From the 150 tested anti HCV positive patients, including samples used in 
genotyping study from 5' UTR region and additional nontyped samples, 29 HCV 
isolates were amplified from part of NS5B region, in an amount suitable for sequencing.   
 
3.3 Sequence Analyses and Genotype Determination 
 
Desalted amplification products were sequenced with same primer pair by using 
Big DyeTM Terminator Cycle Sequencing Ready Reaction Kit. The electropherograms 
were analyzed. The sequence of each sample is given in Appendix A. 
 
All 29 NS5B sequences obtained in this study were aligned with subtype-
specific consensus sequences by Clustal W program (http://workbench.sdsc.edu). The 
imported alignment was used to construct phylogenetic tree (Figure 3.7). Phylogenetic 
tree is the most accurate method to reveal the evolutionary relationships and distances 
between the nucleic acid sequences. However, it is computationally intensive. As we 
aimed to match genotypes identified in the 5' UTR region, we performed the simple 
phylogenetic analysis by parsimony method. Resulting tree was plotted in unrooted 
from. The topology of the resulted tree was similar to that of 5' UTR. It contained 
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6 major phylogenetic branches, composed of clusters of more related sequences.  27 out 
of 29 NS5B sequences were clustered with consensus sequence of subtype 1b. 
Therefore, the genotype of these 27 sequences is subtype 1b. One sample was found 
with under same phylogenetic branch with consensus sequence of subtype 2a and 
another one was grouped with the consensus sequence of subtype 4d. All of the 
determined genotypes tested by sequencing of 5' UTR and NS5B were of the same 
genotype. All 29 HCV isolates, genotyped by partial sequencing from NS5B (in this 
study) and/or from 5' UTR (in previous study), are given in Table 3.4. 17 out of 72 
HCV-1b sequences, typed from 5' UTR, were confirmed and additional 10 HCV 
isolates were determined as subtype 1b in this study. Our results confirmed that the 
predominant genotype is subtype 1b in Turkish population. The other genotypes are 
subtype 2a and genotype 4.  
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Table 3.4: Comparison of NS5B genotyping results with 5' UTR 
genotyping results 
Sample 
Number 
Genotype from 5' 
UTR 
Genotype from 
NS5B 
Conformation 
Status 
8 Subtype 1b Subtype 1b Confirmed 
40 Subtype 1b Subtype 1b Confirmed 
41 Subtype 1b Subtype 1b Confirmed 
60 Subtype 1b Subtype 1b Confirmed 
69 Subtype 1b Subtype 1b Confirmed 
76 Subtype 1b Subtype 1b Confirmed 
78 Subtype 1b Subtype 1b Confirmed 
81 Subtype 1b Subtype 1b Confirmed 
86 Subtype 1b Subtype 1b Confirmed 
87 Subtype 1b Subtype 1b Confirmed 
94 Subtype 1b Subtype 1b Confirmed 
101 Subtype 1b Subtype 1b Confirmed 
103 Subtype 1b Subtype 1b Confirmed 
114 Subtype 2a Subtype 2a  Confirmed 
119 Subtype 1b Subtype 1b Confirmed 
131 Subtype 1b Subtype 1b Confirmed 
135 Subtype 1b Subtype 1b Confirmed 
144   Subtype 1b Subtype 1b Confirmed 
149 ND* Subtype 1b  
155 ND* Subtype 4  
160 ND* Subtype 1b  
167 ND* Subtype 1b  
169 ND* Subtype 1b  
170 ND* Subtype 1b  
211 ND* Subtype 1b  
212 ND* Subtype 1b  
213 ND* Subtype 1b  
215 ND* Subtype 1b  
216 ND* Subtype 1b  
* ND: Not Determined 
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3. 4 Characterization of Turkish isolate of HCV 1b  
 
After establishing that subtype 1b is the predominant genotype in our study 
population, we performed whole genome sequencing of HCV-1b isolate form Turkey. 
Whole genome was cloned as 7 overlapping fragments and partial sequence HCV-1b 
was obtained in a previous study by Aslý Öztan (M.S.Thesis, Molecular Biology and 
Genetics Department, Bilkent University). In order to determine the sequences of the 
remaining regions new sequencing primers were designed and used. In this study, we 
obtained full length sequence of Turkish HCV-1b isolate from a single human carrier. 
Turkish HCV-1b isolate comprises 9361 nucleotides, including 306 nucleotides of 5' 
UTR, a single long open reading frame of 9033 nucleotides, and 22 nucleotides of 3' 
UTR (Figure 3.8). We could not sequence whole 5' UTR and 3' UTR. Open reading 
frame of the HCV-1b isolate is organized from 5' to 3' by genes, that are core, E1, E2, 
NS2, NS3, NS4A, NS4B, NS5A, and NS5B. 
 
The nucleotide sequence of Turkish isolate was translated into amino acid 
sequence. The inferred amino acid sequence is 3010 amino acid long, with no 
insertion/deletion of amino acids in the polyprotein. The polyprotein is composed of 
core (191 amino acids), E1 (192 amino acids), E2 (363 amino acids), p7 (63 amino 
acids), NS2 (217 amino acids), NS3 (631 amino acids), NS4A (54 amino acids), NS4B 
(261 amino acids), NS5A (448 amino acids), NS5B (590 amino acids) proteins. The 
alignment with protein sequence of other 48 HCV-1b isolates at NCBI database 
revealed overall 37 amino acid substitutions, 17 of which only found in Turkish HCV-
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1b isolate. All substitutions are given in Table 3.5.  
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Figure 3.8: Full length Nucleic acid and amino acid sequence of Turkish HCV-1b isolate 
 
5’-ATCACTCCCCTGTGAGGAACTACTGTCTTCACGCAGAAAGCGCCTAG 
CCATGGCGTTAGTATGAGTGTCGTGCAGCCTCCAGGACCCCCCCTCCC 
GGGAGAGCCATAGTGGTCTGCGGAACCGGTGAGTACACCGGAATTGCC 
AGGACGACCGGGTCCTTTCTTGGATCAACCCGCTCAATGCCTGGAGATT 
TGGGCGTGCCCCCGCGAGACTGCTAGCCGAGTAGTGTTGGGTCGCGAA 
AGGCCTTGTGGTACTGCCTGATAGGGTGCTTGCGAGTGCCCCGGGAGGT 
CTCGTAGACCGTGCACC- 
 
ATG AGC ACG AAT CCT AAA CCT CAA AGA AAA ACC AAA CGT AAC ACC AAC 
  M   S   T   N   P   K   P   Q   R   K   T   K   R   N   T   N 
 
CGC CGC CCA CAG GAC GTC AAG TTC CCG GGC GGT GGT CAG ATC GTT GGT 
  R   R   P   Q   D   V   K   F   P   G   G   G   Q   I   V   G 
 
GGA GTT TAC TTG TTG CCG CGC AGG GGC CCC AGG TTG GGT GTG CGC SCG 
  G   V   Y   L   L   P   R   R   G   P   R   L   G   V   R   ? 
 
ACT AGG AAG ACT TCC GAG CGG TCA CAA CCT CGT GGA AGG CGA CAA CCT 
  T   R   K   T   S   E   R   S   Q   P   R   G   R   R   Q   P 
 
ATC CCC AAG GTT CGC CGA CCC GAG GGC AGA GCC TGG GCT CAG CCC GGG 
  I   P   K   V   R   R   P   E   G   R   A   W   A   Q   P   G 
 
TAT CCT TGG CCC CTC TAT GGC AAT GAG GGC WTG GGG TGG GCA GGA TGG 
  Y   P   W   P   L   Y   G   N   E   G   ?   G   W   A   G   W 
 
CTC CTG TCA CCC CGT GGC TCC CGG CCT AGT TGG GGC CCC ACA GAC CCC 
  L   L   S   P   R   G   S   R   P   S   W   G   P   T   D   P 
 
CGG CGT AGG TCG CGT AAT CTG GGT AAG GTC ATC GAT ACC CTC ACA TGC 
  R   R   R   S   R   N   L   G   K   V   I   D   T   L   T   C 
 
GGC TTC GCC GAC CTC ATG GGG TAT ATT CCG CTT GTC GGC GCC CCC CTA 
  G   F   A   D   L   M   G   Y   I   P   L   V   G   A   P   L 
 
GGG GGC GCT GCC AGG GCC CTG GCG CAT GGC GTC CGG GTT CTG GAG GAC 
  G   G   A   A   R   A   L   A   H   G   V   R   V   L   E   D 
 
GGC GTG AAC TAT GCA ACA GGG AAT CTG CCC GGT TGC TCT TTC TCT ATC 
  G   V   N   Y   A   T   G   N   L   P   G   C   S   F   S   I 
 
TTC CTC TTG GCT CTG TTA TCT TGT CTG ACC ATG CCT GCT TCC GCT TAT 
  F   L   L   A   L   L   S   C   L   T   M   P   A   S   A   Y 
 
GAG GTG CGC AAC GTG TCC GGG GCG TAC CAT GTC ACG AAC GAC TGC TCC 
  E   V   R   N   V   S   G   A   Y   H   V   T   N   D   C   S 
 
AAC TCA AGC ATA GTG TAT GAG GCA GCG GAC ATG ATC ATG CAC ACC CCC 
  N   S   S   I   V   Y   E   A   A   D   M   I   M   H   T   P 
 
GGG TGC GTG CCC TGC GTT CGG GAG AAC AAC TCC TCC CGC TGC TGG GTG 
  G   C   V   P   C   V   R   E   N   N   S   S   R   C   W   V 
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Figure 3.8 Continued 
 
GCG CTC ACT CCC ACG CTT GCG GCT AGG AAT GGT AGC GTC CCC ACT ACG 
  A   L   T   P   T   L   A   A   R   N   G   S   V   P   T   T 
 
GCA ATA CGA CGC CAT GTC GAT TTG CTC GTT GGG GCG GCT ACC TTC TGC 
  A   I   R   R   H   V   D   L   L   V   G   A   A   T   F   C 
 
TCC GCT ATG TAC GTG GGG GAT CTC TGC GGA TCT GTT TTC CTT GTT TCC 
  S   A   M   Y   V   G   D   L   C   G   S   V   F   L   V   S 
 
CAG CTG TTC ACC TTC TCG CCT CGC CGG CAT GAG ACA GTG CAG GAC TGC 
  Q   L   F   T   F   S   P   R   R   H   E   T   V   Q   D   C 
 
AAC TGT TCA ATC TAT CCC GGC CAC GTA TCA GGT CAC CGT ATG GCT TGG 
  N   C   S   I   Y   P   G   H   V   S   G   H   R   M   A   W 
 
GAT ATG ATG ATG AAC TGG TCA CCC ACA ACA GCT CTA GTG GTG TCG CAG 
  D   M   M   M   N   W   S   P   T   T   A   L   V   V   S   Q 
 
TTA CTC CGG ATC CCA CAA GCC ATC ATG GAC ATG GTG GCG GGG GCC CAC 
  L   L   R   I   P   Q   A   I   M   D   M   V   A   G   A   H 
 
TGG GGA GTC CTG GCG GGC CTT GCC TAC TAC TCC ATG GTG GGG AAC TGG 
  W   G   V   L   A   G   L   A   Y   Y   S   M   V   G   N   W 
 
GCT AAG GTT TTG ATT GTC ATG CTA CTC TTT GCC GGC GTC GAC GGG GAT 
  A   K   V   L   I   V   M   L   L   F   A   G   V   D   G   D 
 
ACC TAT GTG ACA GGA GGG ACG AGC GGC CGC GCC ACC GCC GGG TTC GTG 
  T   Y   V   T   G   G   T   S   G   R   A   T   A   G   F   V 
 
TCC CTC TTT GCA TCC GGA CCA ACT CAG AGA ATC CAG CTT GTA AAC ACC 
  S   L   F   A   S   G   P   T   Q   R   I   Q   L   V   N   T 
 
AAC GGT AGC TGG CAC ATC AAT AGG ACC GCC CTC AAC TGC AAC GAG TCC 
  N   G   S   W   H   I   N   R   T   A   L   N   C   N   E   S 
 
CTC AAC ACC GGG TTC CTT GCC GCG CTG TTC TAT ACA CAC AAG TTC AAT 
  L   N   T   G   F   L   A   A   L   F   Y   T   H   K   F   N 
 
GCG TCC GGA TGC CCG GAG CGC ATG GCC AGC TGC CGC CCC ATC GAC AAG 
  A   S   G   C   P   E   R   M   A   S   C   R   P   I   D   K 
 
TTC GCT CAG GGA TGG GGT CCT ATC ACC TAC ACC GAG CCC GAG GAC CTG 
  F   A   Q   G   W   G   P   I   T   Y   T   E   P   E   D   L 
 
GAC CAG AGG CCT TAC TGC TGG CAC TAC GCA CCT AGA AAG TGC GGC ATC 
  D   Q   R   P   Y   C   W   H   Y   A   P   R   K   C   G   I 
 
ATA CCC GCG GCG GAG GTG TGC GGC CCA GTA TAC TGC TTC ACC CCG AGC 
  I   P   A   A   E   V   C   G   P   V   Y   C   F   T   P   S 
 
CCT GTC GTG GTG GGG ACA ACC GAT CGG TTC GGC GTT CCT ACG TAT AGA 
  P   V   V   V   G   T   T   D   R   F   G   V   P   T   Y   R 
 
TGG GGG GAG AAC GAG ACG GAC GTG CTG CTC CTC AAC AAC ACG CGG CCA 
  W   G   E   N   E   T   D   V   L   L   L   N   N   T   R   P 
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Figure 3.8 Continued 
 
CCG CAA GGC AAC TGG TTC GGC TGT ACA TGG ATG AAT AGC ACT GGG TTC 
  P   Q   G   N   W   F   G   C   T   W   M   N   S   T   G   F 
 
ACC AAG ACG TGC GGG GGC CCC CCC TGT AAC ATC GGG GGG GCC GGC AAC 
  T   K   T   C   G   G   P   P   C   N   I   G   G   A   G   N 
 
AAC ACC TTG CTA TGC CCC ACG GAT TGC TTC CGG AAG CAC CCC GAC GCC 
  N   T   L   L   C   P   T   D   C   F   R   K   H   P   D   A 
 
ACA TAC ACC AAA TGC GGT TCA GGG CCT TGG TTG ACA CCT AGG TGC ATG 
  T   Y   T   K   C   G   S   G   P   W   L   T   P   R   C   M 
 
GTT GAC TAC CCA TAC AGA CTC TGG CAT TAC CCC TGC ACT GTC AAC TTT 
  V   D   Y   P   Y   R   L   W   H   Y   P   C   T   V   N   F 
 
ACC GTC TTC AAG GTG AGG ATG TAC GTG GGG GGC GTG GAA CAC AGG CTC 
  T   V   F   K   V   R   M   Y   V   G   G   V   E   H   R   L 
 
AGC GCT GCA TGC AAT TGG ACT CGG GGA GAG CGT TGC GAC TTG GAG GAC 
  S   A   A   C   N   W   T   R   G   E   R   C   D   L   E   D 
 
AGG GAC AGA TCG GAG CTC AGC CCG CTG CTG CTG TCT ACA ACA GAG TGG 
  R   D   R   S   E   L   S   P   L   L   L   S   T   T   E   W 
 
CAA GTG TTG CCC TGT TCC TTC ACC ACC TTG CCC GCC CTG TCC ACT GGT 
  Q   V   L   P   C   S   F   T   T   L   P   A   L   S   T   G 
 
TTG ATC CAT CTA CAT CAG AAC ATC GTG GAC GTG CAG TAC CTG TAC GGT 
  L   I   H   L   H   Q   N   I   V   D   V   Q   Y   L   Y   G 
 
ATA GGG TCG GCG GTT GTC TCC TTT GCC ATC AAA TGG GAG TAT ATC CTG 
  I   G   S   A   V   V   S   F   A   I   K   W   E   Y   I   L 
 
CTG CTC TTC CTC CTC CTG GCG TAC GCG CGA GTC TGC GCT TGC CTG TGG 
  L   L   F   L   L   L   A   Y   A   R   V   C   A   C   L   W 
 
ATG ATG CTG CTG ATA GCC CAG GCT GAG GCC GCC CTA GAG ATC CTG GTG 
  M   M   L   L   I   A   Q   A   E   A   A   L   E   I   L   V 
 
GTC CTC AAT GCG GCG TCC GTG GCC GGG GCA CAC GGC ATT CTC TCC TTC 
  V   L   N   A   A   S   V   A   G   A   H   G   I   L   S   F 
 
CTT GTG TTC TTC TGT GCT GCC TGG TAC ATC AAG GGC AGG CTG GTC CCT 
  L   V   F   F   C   A   A   W   Y   I   K   G   R   L   V   P 
 
GGG GCG GCA TAC GCC CTC TAC GGC GTG TGG CCG CTG CTC CTG CTC CTG 
  G   A   A   Y   A   L   Y   G   V   W   P   L   L   L   L   L 
 
CTG GCG TTA CCA CCG CGA GCA TAT GCC ATG GAC CGG GAG ATG GCT GCA 
  L   A   L   P   P   R   A   Y   A   M   D   R   E   M   A   A 
 
TCA TGT GGA GGC GCG GTT TTC ATA GGT CTG GCA ATT TTG ACC TTG TCA 
  S   C   G   G   A   V   F   I   G   L   A   I   L   T   L   S 
 
CCG CAC TAT AAG GTG CTC CTA GCA AAA CTT ATA TGG TGG TCA CAA TAC 
  P   H   Y   K   V   L   L   A   K   L   I   W   W   S   Q   Y 
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TTT ATC ACC AGG GCC GAG GCG CAT GTG CAA GTG TGG ACC CCC CCC CTC 
  F   I   T   R   A   E   A   H   V   Q   V   W   T   P   P   L 
 
AAC GTT CGG GGG GGC CGT GAT GCC ATC ATC CTC CTC ACT TGC GCG GTC 
  N   V   R   G   G   R   D   A   I   I   L   L   T   C   A   V 
 
CAC CCA GAG CTA ATC TTT GAA ATC ACC AAG ATT TTG CTC GCC GTG CTC 
  H   P   E   L   I   F   E   I   T   K   I   L   L   A   V   L 
 
GGT CCG CTC ATG GTA CTC CAG GCT GGC ATA ACC AGA GTG CCG TAC TTT 
  G   P   L   M   V   L   Q   A   G   I   T   R   V   P   Y   F 
 
GTG CGC GCT CAG GGC CTC ATT CGT GTG TGC ATG TTG GTG CGG AAA GCC 
  V   R   A   Q   G   L   I   R   V   C   M   L   V   R   K   A 
 
GCT GGG GGT CAT TAC GTC CAA ATG GCC CTC ATG AGG TTG GGC GCC CTG 
  A   G   G   H   Y   V   Q   M   A   L   M   R   L   G   A   L 
 
ACA GGC ACG TAC CTT TAT GAC CAT CTT ACT CCA CTG CGG GAC TGG GCC 
  T   G   T   Y   L   Y   D   H   L   T   P   L   R   D   W   A 
 
CAC GCG GGC CTG CGG GAC CTC GCG GTG GCA GTT GAG CCC GTC ATC TTC 
  H   A   G   L   R   D   L   A   V   A   V   E   P   V   I   F 
 
TCT GAC ATG GAG ACC AAG GTC ATC ACC TGG GGG GCA GAC ACC GCG GCG 
  S   D   M   E   T   K   V   I   T   W   G   A   D   T   A   A 
 
TGT GGG GAC ATC ATC TCG GGC CTA CCC GTC TCC GCC CGA AGG GGG AGG 
  C   G   D   I   I   S   G   L   P   V   S   A   R   R   G   R 
 
GAG ATA CTT CTA GGA CCG GCC GAT AGC TTT AAG GGG CAG GGA TGG CGA 
  E   I   L   L   G   P   A   D   S   F   K   G   Q   G   W   R 
 
CTC CTT GCG CCT ATT ACG GCC TAC TCC CAG CAG ACG CGG GGC CTA CTT 
  L   L   A   P   I   T   A   Y   S   Q   Q   T   R   G   L   L 
 
GGC TGC ATC ATC ACT AGC CTC ACA GGC CGG GAT AAG AAC CAG GTC GAG 
  G   C   I   I   T   S   L   T   G   R   D   K   N   Q   V   E 
 
GGG GAA GTC CAA GTG GTT TCC ACC GCA ACC CAG TCT TTC CTA GCA ACC 
  G   E   V   Q   V   V   S   T   A   T   Q   S   F   L   A   T 
 
TGT GTC AGC GGC GCG TGT TGG ACT GTC TAC CAT GGT GCC GGC TCA AAG 
  C   V   S   G   A   C   W   T   V   Y   H   G   A   G   S   K 
 
ACC CTA GCT GGC CCG AAA GGA CCA ATC ACC CAA ATG TAC ACC AAT GTA 
  T   L   A   G   P   K   G   P   I   T   Q   M   Y   T   N   V 
 
GAC CAG GAT CTC GTC GGC TGG CCG GCG CCC CCT GGG GCG CGC TCC TTG 
  D   Q   D   L   V   G   W   P   A   P   P   G   A   R   S   L 
 
ACG CCA TGC ACC TGC GGC AGC TCG GAC CTT TAC TTG GTC ACG AGG CAT 
  T   P   C   T   C   G   S   S   D   L   Y   L   V   T   R   H 
 
GCC GAT GTC ATT CCG GTG CGC CGG CGG GGC GAC AGC AGG GGG AGC CTG 
  A   D   V   I   P   V   R   R   R   G   D   S   R   G   S   L 
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CTC TCT CCC AGG CCC ATC TCC TAT TTA AAG GGT TCT TCG GGT GGA CCA 
  L   S   P   R   P   I   S   Y   L   K   G   S   S   G   G   P 
 
CTG CTC TGC CCC TCG GGG CAC GCT GTG GGC ATC TTC CGG GCT GCT GTG 
  L   L   C   P   S   G   H   A   V   G   I   F   R   A   A   V 
 
TGC ACC CGG GGG GTT GCC AAG GCG GTG GAC TTT GTA CCC GTT GAG TCC 
  C   T   R   G   V   A   K   A   V   D   F   V   P   V   E   S 
 
ATG GAA ACC ACT ATG CGG TCT CCG GTC TTC ACG GAC AAC TCG TCC CCC 
  M   E   T   T   M   R   S   P   V   F   T   D   N   S   S   P 
 
CCG GCC GTA CCG CAG ACA TTC CAA GTG GCC CAT CTG CAC GCT CCC ACT 
  P   A   V   P   Q   T   F   Q   V   A   H   L   H   A   P   T 
 
GGC AGC GGT AAG AGC ACT AAG GTG CCG GCT GCA TAC GCA GCC CAA GGG 
  G   S   G   K   S   T   K   V   P   A   A   Y   A   A   Q   G 
 
TAC AAG GTA CTC GTC CTG AAC CCG TCC GTT GCC GCT ACC TTA AGT TTC 
  Y   K   V   L   V   L   N   P   S   V   A   A   T   L   S   F 
 
GGG GCG TAT ATG TCC AAG GCA CAT GGT GTC GAA CCC AAC ATT AGA ACT 
  G   A   Y   M   S   K   A   H   G   V   E   P   N   I   R   T 
 
GGG GTA AGG ACC GTC ACC ACG GGC GCC GGC ATT ACG TAT TCC ACC TAC 
  G   V   R   T   V   T   T   G   A   G   I   T   Y   S   T   Y 
 
GGC AAG TTC CTT GCT GAT GGC GGT TGC TCT GGA GGC GCC TAT GAC ATC 
  G   K   F   L   A   D   G   G   C   S   G   G   A   Y   D   I 
 
ATA ATA TGT GAT GAG TGC CAC TCA ACT GAC TCG ACT ACC ATC TTG GGC 
  I   I   C   D   E   C   H   S   T   D   S   T   T   I   L   G 
 
ATC GGC ACG GTC CTG GAC CAA GCG GAG ACG GCT GGA GCG CGA CTC GTC 
  I   G   T   V   L   D   Q   A   E   T   A   G   A   R   L   V 
 
GTG CTC GCC ACC GCT ACG CCT CCG GGA TCG GTC ACC GTG CCA CAT CCC 
  V   L   A   T   A   T   P   P   G   S   V   T   V   P   H   P 
 
AAC ATT GAG GAG GTG GCC CTG TCC AAC ACT GGA GAG ATC CCC TTC TAT 
  N   I   E   E   V   A   L   S   N   T   G   E   I   P   F   Y 
 
GGC AAA GCC ATC CCC GTT GAG GTC ATC AAG GGG GGA AGG CAT CTC ATT 
  G   K   A   I   P   V   E   V   I   K   G   G   R   H   L   I 
 
TTC TGC CAC TCC AAG AAG AAA TGT GAC GAG CTC GCC GCA AAA CTG TCG 
  F   C   H   S   K   K   K   C   D   E   L   A   A   K   L   S 
 
GGC CTC GGA CTC AAT GCT GTA GCG TAT TAC CGG GGC CTT GAT GTG TCC 
  G   L   G   L   N   A   V   A   Y   Y   R   G   L   D   V   S 
 
GTC ATA CCG ACC AGC GGA GAC GTC GTT GTC GTA GCA ACT GAC GCT CTA 
  V   I   P   T   S   G   D   V   V   V   V   A   T   D   A   L 
 
ATG ACG GGC TTT ACT GGC GAC TTT GAC TCA GTG ATC GAC TGT AAC ACG 
  M   T   G   F   T   G   D   F   D   S   V   I   D   C   N   T 
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TGT GTC ACC CAA ACA GTC GAT TTC AGC CTG GAC CCC ACC TTC ACC ATC 
  C   V   T   Q   T   V   D   F   S   L   D   P   T   F   T   I 
 
GAA ACG ACG ACC GTG CCC CAG GAC GCA GTG TCG CGC TCG CAG CGG CGG 
  E   T   T   T   V   P   Q   D   A   V   S   R   S   Q   R   R 
 
GGC AGG ACT GGC AGG GGC AGG GCA GGC ATC TAC AGG TTT GTG ACT CCG 
  G   R   T   G   R   G   R   A   G   I   Y   R   F   V   T   P 
 
GGA GAA CGG CCT TCG GGC ATG TTC GAC TCT TCG GTC CTG TGC GAG TGC 
  G   E   R   P   S   G   M   F   D   S   S   V   L   C   E   C 
 
TAT GAC GCG GGC TGT GCA TGG TAC GAG CTT ACG CCC GCC GAG ACC TCA 
  Y   D   A   G   C   A   W   Y   E   L   T   P   A   E   T   S 
 
GTT AGG GTA CGG GCT TAC CTA AAT ACA CCA GGG TTG CCC GTC TGC CAG 
  V   R   V   R   A   Y   L   N   T   P   G   L   P   V   C   Q 
 
GAC CAC TTG GAG TTC TGG GAA AGC GTC TTT ACA GGC CTT ACC CAC ATA 
  D   H   L   E   F   W   E   S   V   F   T   G   L   T   H   I 
 
GAT GCT CAC TTC TTG TCC CAG ACT AAG CAG GCA GGA GAC AAC TTC CCC 
  D   A   H   F   L   S   Q   T   K   Q   A   G   D   N   F   P 
 
TAT CTG GTA GCA TAC CAG GCT ACG GTG TGC GCC AGG GCC CAG GCC CCA 
  Y   L   V   A   Y   Q   A   T   V   C   A   R   A   Q   A   P 
 
CCT CCA TCA TGG GAT CAA ATG TGG AAG TGC CTC ATA CGG CTA AAA CCT 
  P   P   S   W   D   Q   M   W   K   C   L   I   R   L   K   P 
 
ACG CTG CAC GGA CCA ACG CCC CTG CTG TAT AGG ATG GGA GCC GTC CAA 
  T   L   H   G   P   T   P   L   L   Y   R   M   G   A   V   Q 
 
AAC GAG GTC AAC CTC ACA CAC CCC GTA ACC AAA TAC ATC ATG GCA TGC 
  N   E   V   N   L   T   H   P   V   T   K   Y   I   M   A   C 
 
ATG TCG GCT GAC CTG GAG GTC GTC ACC AGC ACC TGG GTG CTT GTA GGC 
  M   S   A   D   L   E   V   V   T   S   T   W   V   L   V   G 
 
GGG GTC CTC GCG GCT CTG GCC GCA TAT TGT TTG ACA ACA GGC AGC GTG 
  G   V   L   A   A   L   A   A   Y   C   L   T   T   G   S   V 
 
GTC ATT GTG GGC AGG ATC ATC TTG TCC GGA AAG CCG GCA ATC ATT CCC 
  V   I   V   G   R   I   I   L   S   G   K   P   A   I   I   P 
 
GAC AGG GAA GCT CTC TAC CAG GCG TTC GAT GAG ATG GAG GAG TGC GCC 
  D   R   E   A   L   Y   Q   A   F   D   E   M   E   E   C   A 
 
TCA CAC CTC CCT TAC ATC GAA CAG GGA ATG CAA CTC GCC GAG CAA TTC 
  S   H   L   P   Y   I   E   Q   G   M   Q   L   A   E   Q   F 
 
AAG CAG AAG GCG CTC GGG TTG TTG CAA ACA GCG ACC AAA CAA GCG GAG 
  K   Q   K   A   L   G   L   L   Q   T   A   T   K   Q   A   E 
 
GCC GCT GCT CCC GTG GTG GAG TCC AAG TGG CGG GCC CTT GAG ACC TTC 
  A   A   A   P   V   V   E   S   K   W   R   A   L   E   T   F 
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TGG GCG AAG CAC ATG TGG AAC TTC ATT AGC GGG ATA CAG TAC TTA GCA 
  W   A   K   H   M   W   N   F   I   S   G   I   Q   Y   L   A 
 
GGC TTG TCC ACT CTG CCT GGG AAC CCC GCA ATA GCA TCA CTG ATG GCA 
  G   L   S   T   L   P   G   N   P   A   I   A   S   L   M   A 
 
TTC ACA GCC TCT ATC ACT AGC CCG CTC ACC ACT CAA CAC ACC CTC CTG 
  F   T   A   S   I   T   S   P   L   T   T   Q   H   T   L   L 
 
TTT AAT ATC TTG GGG GGA TGG GTA GCC GCC CAA CTC GCG CCC CCC AGC 
  F   N   I   L   G   G   W   V   A   A   Q   L   A   P   P   S 
 
GCC GCT TCT GCC TTC GTG GGC GCC GGC ATT GCA GGT GCG GCT GTT GGC 
  A   A   S   A   F   V   G   A   G   I   A   G   A   A   V   G 
 
AGT ATA GGC CTT GGG AAA GTG CTT GTG GAC ATC CTG GCG GGC TAT GGA 
  S   I   G   L   G   K   V   L   V   D   I   L   A   G   Y   G 
 
GCG GGG GTG GCA GGC GCG CTC GTG GCC TTT AAG GTC ATG AGT GGC GAG 
  A   G   V   A   G   A   L   V   A   F   K   V   M   S   G   E 
 
ATG CCC TCT ACA GAG GAT CTG GTC AAC TTA CTC CCT GCT ATC CTC TCT 
  M   P   S   T   E   D   L   V   N   L   L   P   A   I   L   S 
 
CCT GGT GCC CTG GTC GTC GGA GTC GTG TGC GCA GCA ATA CTG CGG CGG 
  P   G   A   L   V   V   G   V   V   C   A   A   I   L   R   R 
 
CAT GTG GGC CCA GGA GAG GGG GCG GTA CAA TGG ATG AAC CGG CTG ATA 
  H   V   G   P   G   E   G   A   V   Q   W   M   N   R   L   I 
 
GCG TTC GCT TCA CGG GGT AAC CAC GTT TCC CCC ACG CAC TAC GTG CCT 
  A   F   A   S   R   G   N   H   V   S   P   T   H   Y   V   P 
 
GAG AGC GAC GCT GCA GCG CGT GTC ACT CAG ATC CTC TCT AGC CTT ACC 
  E   S   D   A   A   A   R   V   T   Q   I   L   S   S   L   T 
 
ATC ACT CAG CTG CTG AAG AGG CTC CAC CAG TGG ATT AAT GAG GAC TGC 
  I   T   Q   L   L   K   R   L   H   Q   W   I   N   E   D   C 
 
TCC ACG CCG TGT TCC GGC TCG TGG CTA AGG GAC ATC TGG GAC TGG ATA 
  S   T   P   C   S   G   S   W   L   R   D   I   W   D   W   I 
 
TGC ACG GTG TTG TCT GAC TTC AAG ACC TGG CTC CAG TCC AAG CTT CTG 
  C   T   V   L   S   D   F   K   T   W   L   Q   S   K   L   L 
 
CCG CGG TTA CCG GGA GTC CCC TTC TTC TCA TGC CAA CGT GGG TAT AAG 
  P   R   L   P   G   V   P   F   F   S   C   Q   R   G   Y   K 
 
GGA GTC TGG CGC GGA GAC GGC ATC ATG CAC ACC ACC TGT TCA TGT GGG 
  G   V   W   R   G   D   G   I   M   H   T   T   C   S   C   G 
 
GCA CAG ATC ACC GGA CAT GTC AAA AAC GGT TCC ATG AGG ATC GTT GGG 
  A   Q   I   T   G   H   V   K   N   G   S   M   R   I   V   G 
 
CCA AAA ACC TGC AGT AAC ACG TGG CAT GGA ACA TTT CCC ATC AAC GCG 
  P   K   T   C   S   N   T   W   H   G   T   F   P   I   N   A 
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TAC ACC ACG GGC CCT TGC ACA CCC TCC CCA GCG CCA AAC TAT ACT AGG 
  Y   T   T   G   P   C   T   P   S   P   A   P   N   Y   T   R 
 
GCG CTG TGG AGG GTG GCC GCA GAG GAG TAC GTG GAG GTT ACG CGG GTG 
  A   L   W   R   V   A   A   E   E   Y   V   E   V   T   R   V 
 
GGG GAT TTC CAC TAC GTG ACG GGC ATG ACC ACC GAC AAC GTC AAG TGC 
  G   D   F   H   Y   V   T   G   M   T   T   D   N   V   K   C 
 
CCA TGC CAG GTT CCG GCC CCC GAA TTC TTC ACA GAA GTG GAT GGG GTG 
  P   C   Q   V   P   A   P   E   F   F   T   E   V   D   G   V 
 
CGG CTG CAT AGG TAC GCT CCG GCG TGC AAA CCC CTC CTA CGG GAG GAG 
  R   L   H   R   Y   A   P   A   C   K   P   L   L   R   E   E 
 
GTC ACA TTC CAG GTC GGG CTC AAC CAG TAT CTG GTC GGG TCG CAG CTT 
  V   T   F   Q   V   G   L   N   Q   Y   L   V   G   S   Q   L 
 
CCG TGT GAG CCC GAG CCG GAC GTG ACA ACG CTC ACC TCC ATG CTC ATC 
  P   C   E   P   E   P   D   V   T   T   L   T   S   M   L   I 
 
GAC CCC TCC CAC ATC ACA GCA GAG ACT GCT AAG CGT AGG TTG GCC AGA 
  D   P   S   H   I   T   A   E   T   A   K   R   R   L   A   R 
 
GGG TCT CCC CCC TCC TTG GCC AGC TCC TCA GCT AGC CAG TTA TCT GCG 
  G   S   P   P   S   L   A   S   S   S   A   S   Q   L   S   A 
 
CCT TCC CTG AAG GCG ACA TGC ACC ACT CAC CAT GAC TCC CCA GAC GCT 
  P   S   L   K   A   T   C   T   T   H   H   D   S   P   D   A 
 
GAC CTC ATT GAG GCC AAC CTC CTG TGG CGG CAG GAG ATG GGC GGA AAC 
  D   L   I   E   A   N   L   L   W   R   Q   E   M   G   G   N 
 
ATC ACC CGC GTG GAG TCT GAG AAC AAG GTA GTA ATC CTG GAC TCT TTC 
  I   T   R   V   E   S   E   N   K   V   V   I   L   D   S   F 
 
GAC CCG CTT CGA GCG GAG GAG GAC GAA AGG GAA GTG TCC GTT CCA GCG 
  D   P   L   R   A   E   E   D   E   R   E   V   S   V   P   A 
 
GAG ATC CTG CGG AAA TCC AGG AGA TTC CCT TCA GCG ATG CCC GTG TGG 
  E   I   L   R   K   S   R   R   F   P   S   A   M   P   V   W 
 
GCA CGC CCA GAT TAC AAC CCT CCA TTG CTA GAG TCT TGG GAG AAC CCG 
  A   R   P   D   Y   N   P   P   L   L   E   S   W   E   N   P 
 
GAC TAC GTC CCT CCA GTG GTA CAC GGG TGC CCA TTG CCA CCT ACT AAG 
  D   Y   V   P   P   V   V   H   G   C   P   L   P   P   T   K 
 
GCC CCA CCA ATA CCA CCT CCA CGG AGG AAG AGG ACG GTT GTC CTG ACA 
  A   P   P   I   P   P   P   R   R   K   R   T   V   V   L   T 
 
GAA TCC ACC GTG TCT TCC GCC CTG GCG GAG CTT GCT ACT AAG ACC TTC 
  E   S   T   V   S   S   A   L   A   E   L   A   T   K   T   F 
 
GGT AGC TCC GGA TCG TCA GCC GTT GAC AGC GGC ACG GCG ACC GCC CCT 
  G   S   S   G   S   S   A   V   D   S   G   T   A   T   A   P 
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CCC GAC CAG TCC CCC GAC GAC GGC GAC GCA GGG TCT GAC GCT GGG TCG 
  P   D   Q   S   P   D   D   G   D   A   G   S   D   A   G   S 
 
TAC TCC TCC ATG CCC CCC CTT GAG GGG GAG CCG GGG GAT CCC GAT CTC 
  Y   S   S   M   P   P   L   E   G   E   P   G   D   P   D   L 
 
AGC GAC GGG TCC TGG TCT ACC GTG AGC GAG GAG GCT AGT GAG GAC GTC 
  S   D   G   S   W   S   T   V   S   E   E   A   S   E   D   V 
 
GTT TGC TGC TCG ATG TCC TAC ACA TGG ACA GGC GCC CTG ATC ACG CCA 
  V   C   C   S   M   S   Y   T   W   T   G   A   L   I   T   P 
 
TGC GCC GCG GAG GAG AGC AAG CTG CCC ATC AAT GCG CTG AGC AAC TCT 
  C   A   A   E   E   S   K   L   P   I   N   A   L   S   N   S 
 
TTG CTG CGT CAC CAT AAC ATG GTG TAC GCC ACA ACA TCC CGC AGC GCA 
  L   L   R   H   H   N   M   V   Y   A   T   T   S   R   S   A 
 
AGT CAG CGG CAG AAG AAG GTC ACC TTT GAC AGA CTG CAG GTC CTG GAT 
  S   Q   R   Q   K   K   V   T   F   D   R   L   Q   V   L   D 
 
GAC CAT TAC CGG GAC GTG CTT AAG GAG ATG AAG GCG GAG GCG TCC ACA 
  D   H   Y   R   D   V   L   K   E   M   K   A   E   A   S   T 
 
GTT AAG GCT AAA CTT CTA TCC GTG GAA GAA GCC TGC AAG CTG ACG CCC 
  V   K   A   K   L   L   S   V   E   E   A   C   K   L   T   P 
 
CCA CAC TCG GCC AAG TCT AAA TTT GGC TAT GGG GCA AAG GAC GTC CGG 
  P   H   S   A   K   S   K   F   G   Y   G   A   K   D   V   R 
 
AAC CTA TCC AGC AAG SCC GTT AAC CAC ATC CGC TCC GTG TGG GAG GAC 
  N   L   S   S   K   ?   V   N   H   I   R   S   V   W   E   D 
 
CTG CTG GAA GAC ACT GAG ACA CCA ATC GAG ACC GTC ATC ATG GCA AAA 
  L   L   E   D   T   E   T   P   I   E   T   V   I   M   A   K 
 
AAT GAG GTT TTC TGC GTC AAA CCA RAA ATG GRA GGC CGC ARG CCA GCT 
  N   E   V   F   C   V   K   P   ?   M   ?   G   R   ?   P   A 
 
CGY TTA ATC GGG TTC CCA GAC TTG GGG GTT CGT GTA TGC GAG AAA ATG 
  ?   L   I   G   F   P   D   L   G   V   R   V   C   E   K   M 
 
GCC CTC TAC GAC GTG GTC TCC ACC CTT CCT CAG GCC GTG ATG GGC TCC 
  A   L   Y   D   V   V   S   T   L   P   Q   A   V   M   G   S 
 
TCA TAT GGA TTC CAG TAC TCT CCT GCA CAG CGG GTC GAG TTC CTG GTG 
  S   Y   G   F   Q   Y   S   P   A   Q   R   V   E   F   L   V 
 
AAT GCC TGG AAA TCA AAG AAA AAC CCT ATG GGT TTC TCG TAT GAC ACC 
  N   A   W   K   S   K   K   N   P   M   G   F   S   Y   D   T 
 
CGC TGT TTT GAC TCG ACG GTT ACT GAG AAT GAC ATC CGT GTT GAG GAG 
  R   C   F   D   S   T   V   T   E   N   D   I   R   V   E   E 
 
TCA ATT TAT CAA TGT TGT GAC TTG ACC CCC GAA GCC AGA CAG GCT ATA 
  S   I   Y   Q   C   C   D   L   T   P   E   A   R   Q   A   I 
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AGG TCG CTC ACG GAG CGG CTT TAC ATC GGG GGC CCC ATG ACC AAT TCA 
  R   S   L   T   E   R   L   Y   I   G   G   P   M   T   N   S 
 
AAA GGG CAG AAC TGC GGT TAT CGC CGG TGC CGC GCG AGC GGC GTG CTG 
  K   G   Q   N   C   G   Y   R   R   C   R   A   S   G   V   L 
 
ACG ACT AGC TGC GGT AAT ACC CTC ACA TGT TAC TTG AAA GCC TCT GCG 
  T   T   S   C   G   N   T   L   T   C   Y   L   K   A   S   A 
 
GCC TGT CGA GCT GCA AAG CTC CAG AGC TGC ACG ATG CTC GTG AAC GGA 
  A   C   R   A   A   K   L   Q   S   C   T   M   L   V   N   G 
 
GAC GAC CTC GTC GTT ATC TGT GAG AGC GCG GGA ACC CAA GAG GAC GCG 
  D   D   L   V   V   I   C   E   S   A   G   T   Q   E   D   A 
 
GCG AGC CTA CGA GTC TTC ACG GAG GCT ATG ACT AGG TAC TCT GCC CCC 
  A   S   L   R   V   F   T   E   A   M   T   R   Y   S   A   P 
 
CCC GGG GAC CTG CCC CAA CCA GAA TAC GAC TTG GAG TTG ATA ACA TCA 
  P   G   D   L   P   Q   P   E   Y   D   L   E   L   I   T   S 
 
TGC TCC TCC AAT GTG TCA GTC GCG CAC GAT GCA TCT GGC AAA AGA GTA 
  C   S   S   N   V   S   V   A   H   D   A   S   G   K   R   V 
 
TAC TAC CTC ACC CGC GAC CCC ACC ACC CCC CTT GCA CGG GCT GCG TGG 
  Y   Y   L   T   R   D   P   T   T   P   L   A   R   A   A   W 
 
GAG ACA GCT AGA CAC ACT CCA GTT AAC TCC TGG CTA GGC AAC ATC ATC 
  E   T   A   R   H   T   P   V   N   S   W   L   G   N   I   I 
 
ATG TAC GCG CCC ACC ATA TGG GCA AGG ATG ATT CTG ATG ACT CAC TTC 
  M   Y   A   P   T   I   W   A   R   M   I   L   M   T   H   F 
 
TTT TCC ATC CTT CTA GTC CAG GAG CAA CTT GAG AAA GCC CTA GAT TGT 
  F   S   I   L   L   V   Q   E   Q   L   E   K   A   L   D   C 
 
CAG ATC TAC GGG GCC TAT TAC TCC ATT GAG CCA CTT GAC CTA CCT CAG 
  Q   I   Y   G   A   Y   Y   S   I   E   P   L   D   L   P   Q 
 
ATC ATT CAA CGA CTC CAT GGT CTT AGC GCA TTC TCA CTC CAC AGT TAC 
  I   I   Q   R   L   H   G   L   S   A   F   S   L   H   S   Y 
 
CCT CCA GGT GAG ATC AAT AGG GTG GCT TCA TGC CTC AGG AAA CTT GGG 
  P   P   G   E   I   N   R   V   A   S   C   L   R   K   L   G 
 
GTA CCG CCC TTG CGA GTC TGG AGA CAT CGG GCC AGA AGT GTC CGC GCT 
  V   P   P   L   R   V   W   R   H   R   A   R   S   V   R   A 
 
AAG CTA CTG TCT CAG GGG GGG AGG GCT GCC ACA TGT GGT AGA TAC CTC 
  K   L   L   S   Q   G   G   R   A   A   T   C   G   R   Y   L 
 
TTC AAC TGG GCA GTA AGG ACC AAG CTC AAA CTC ACT CCA ATT CCG GCT 
  F   N   W   A   V   R   T   K   L   K   L   T   P   I   P   A 
 
GCA TCT CGG TTG GAC TTG TCC GGC TGG TTT GTT GCT GGT TAC AGC GGG 
  A   S   R   L   D   L   S   G   W   F   V   A   G   Y   S   G 
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Figure 3.8 Continued 
 
GGA GAC ATA TAT CAC AGC CTG TCT CGT GCC CGA CCC CGC TGG TTT ATG 
  G   D   I   Y   H   S   L   S   R   A   R   P   R   W   F   M 
 
TTG TGC CTC TTC CTA CTT TCC GTA GGG GTA GGC ATC TAT CTG CTC CCC 
  L   C   L   F   L   L   S   V   G   V   G   I   Y   L   L   P 
 
AAC CGA TGA -ACGGGGAGCCAACCACTCCAGG-3' 
 
  N   R   - 
 
 
X: represents the noncoding regions (5' UTR and 3' UTR) of HCV Genome 
X: substituted amino acid 
X: substituted amino acid (only observed in Turkish HCV-1b isolate) 
X: conserved cysteine residues 
? : denotes the amino  acids that are not  determined due to ambiguities in the 
nucleotide sequence. 
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Table 3.5: Summary of codon differences between the HCV-1b Turkish isolate and 
other characterized HCV-1b genomes 
Region Variable 
Codon 
Codon 
Number 
Amino Acid Change 
   Turkish HCV-
1b Isolate 
Other 
Reference 
Sequences 
Core ATG 187 M I, T, V 
E2 GCC 397 A F, G, H, I, L, 
M, Q, R, S, Y 
E2 GAG 478 E D, G, H, N, Q, 
R, S, V 
E2 AAG 493 K P, Q, R 
E2 CTA 580 L I, T 
E2 GAC 591 D E 
E2 GTC 626 V I, L 
E2 TAC 728 Y D 
E2 ATC 750 I N 
NS2 ATT 828 I F, L 
NS2 GTG 857 V L, M 
NS2 ACC 861 T I, V 
NS2 CTT 949 L I, V 
NS3 AGC 1075 S N 
NS3 GGC 1290 G P, S 
NS3 GTT 1382 V I, L 
NS3 GTA 1539 V L 
NS3 ATG 1628 M L 
NS3 AAC 1636 N I, T, V 
NS4A GCG 1704 A E 
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Region Variable 
Codon 
Codon 
Number 
Amino Acid Change 
   Turkish HCV-
1b Isolate 
Other 
Reference 
Sequences 
NS5A TCA 2030 S P, Q 
NS5A ACT 2079 T S, F 
NS5A ACG 2170 T V 
NS5A ATC 2176 I T 
NS5A GAG 2302 E K, R 
NS5B GAG 2493 E K 
NS5B GAG 2554 E D, N, Q 
NS5B GTC 2556 V T 
NS5B AAA 2567 K Q 
NS5B ATG 2570 M K 
NS5B GGG 2580 G V 
NS5B GCA 2617 A G, K 
NS5B ACC 2665 T A, S, V 
NS5B AGC 2736 S D, N  
NS5B ATA 2838 I L 
NS5B CCT 2897 P S 
NS5B TTC 2996 F L 
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To characterize the Turkish HCV-1b isolate we examined the amino acid 
changes at number of functional sites, proteolytic cleavage sites, interferon sensitivity 
determining region, and conserved cysteine residues in E1 and E2 regions.  
 
HCV genome encodes a large polyprotein, containing core, E1, E2, NS2, NS3, 
NS4A, NS5A, and NS5B proteins. Structural proteins (core, E1, and E2) of HCV are 
cleaved by host signal peptidases, whereas nonstructural proteins are processed by HCV 
encoded proteases, namely, NS2-NS3 and NS3 proteases. NS2-NS3 protease cleaves 
the NS2/NS3 boundary and the remaining boundaries (NS3/NS4A, NS4A/NS4B, 
NS4B/NS5A, NS5A/NS5B) are processed by the NS3 protease. Both of the enzymes 
mediate the proteolytic cleavage sites with consensus sequence D/E-X4-T/C ↓ S/A.   
The amino acid sequence at the proteolytic cleavage sites is important for proper 
processing of HCV polyprotein to generate functional proteins. Therefore, we examined 
the amino acid sequence of Turkish isolate at the proteolytic cleavage sites. The 
inferred amino acids of Turkish HCV-1b isolate at the cleavage sites were aligned with 
that of 1b HCV-J and 1b HCV- BK isolates and given in Table 3.6. High conservation 
of amino acids sequence was observed. There were only 3 amino acid substitutions.  
 
Sequence comparisons of full length HCV genome revealed a small region in C 
terminus of NS5A that is associated with sensitivity to interferon treatment. This region 
was called as interferon sensitivity determining region (ISDR) and spans the amino acid 
residues 2209 to 2248. The numbering was done, based on amino acid sequence of 
HCV-J subtype 1b strain. Isolates with an ISDR sequence that was the same with that of 
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HCV-J strain, were called wild type and they were resistant to interferon. Isolates with 
more than 4 amino acid substitutions in this region, termed as mutant, were responsive 
to interferon (Enomoto et al., 1996). We compared the ISDR of Turkish Isolate with 
that of HCV-J and HCV-BK strains. We found a single amino acid change between 
HCV-BK and Turkish HCV-1b isolate. The ISDR of Turkish isolate was found to be 
identical to that of HCV J isolate (given in Table 3.7). 
 
We also examined 26 cysteine residues in E1 and E2 proteins, which are 
conserved among several types of HCV (Okamoto et al., 1992c). All of the cysteine 
residues were conserved in Turkish HCV-1b isolate (All cysteine residues are indicated 
in Figure 3.8). 
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Table 3.6: Comparison of inferred amino acids at proteolytic cleavage sites. 
Genotype NS2/NS3    NS3/NS4A  
HCV-1b* ADSFKGQGWRLL ↓ APITAY  MACMSADLEVVT ↓ STWVLV 
HCV-J  ADSFGEQGWRLL ↓ APITAY  MACMSADLEVVT ↓ STMVLV 
HCV-BK ADSLEGRGLRLL ↓ APITAY  MACMSADLEVVT ↓ STMVLV 
Genotype NS4A/ NS4B    N4SB/NS5A  
HCV-1b* ALYQAFDEMEEC ↓ ASHLPY  HQWINEDCSTPC ↓ SGSWLR 
HCV-J  VLYQEFDEMEEC ↓ ASHPLY  HQWINEDCSTPC ↓ SGSWLK 
HCV-BK LLYQEFDEMEEC ↓ ASHPLY  HQWINEDCSTPC ↓ SGSWLR 
Genotype NS5A/NS5B  
HCV-1b* SEEASEDVVCC ↓ SMSYTW 
HCV-J  SGEAGEDVVCC ↓ SMSYTW 
HCV-BK SEEASEDVVCC ↓ SMSYTW 
 
↓ : denotes cleavage sites 
* HCV-1b Turkish isolate, amino acid differences between other two HCV-1b isolates 
are indicated in bold.  
 
 
Table 3.7: Comparison of inferred amino acid sequences at interferon sensitivity 
determining region 
HCV-1b*  PSLKATCTTHHDSPDADLIEANLLWRQEMGGNITRVESEN 
HCV-J  PSLKATCTTHHDSPDADLIEANLLWRQEMGGNITRVESEN 
HCV-BK PSLKATCTTHHVSPDADLIEANLLWRQEMGGNITRVESEN 
 
*HCV-1b Turkish isolate. Single amino acid change between HCV-BK and Turkish 
isolate is indicated in bold.  
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4. DISCUSSION 
 
In this study, we determined the genotypes of HCV isolates from anti HCV 
positive patients residing in South Anatolia and Southeast Anatolia regions of Turkey 
by sequencing part of the NS5B of the HCV genome after PCR amplification to validate 
results obtained with the 5' UTR. 
 
The results of the former study including amplification of part of 5' UTR and 
subsequent phylogenetic analysis indicated that the predominant genotype in South 
Anatolia and Southeast Anatolia of Turkey is subtype 1b with 91.1% prevalence rate. 
The genotype 1a has a prevalence rate of 6%, while genotypes 2a and 4 are seen very 
rarely (1/79 for each case). 
 
The results of this former study showed that 97% of anti HCV positive patients 
are infected with genotype 1. Due to high percentage of HCV-1b and limitations of 5' 
UTR in discrimination between subtype 1a and subtype 1b, confirmation of the results 
from NS5B region was provided in this study. NS5B region was chosen, because it is 
sufficiently variable to differentiate between different types and subtypes of HCV, 
including the subtypes 1a and 1b. There are large numbers of previously published 
sequences that can be obtained from NCBI database, which allows efficient sequence 
comparisons for identification of genotypes and new variants of HCV. This region can 
be readily amplified with PCR.  
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Our results confirmed that predominant genotype in South Anatolia and 
Southeast Anatolia regions of Turkey as subtype 1b. Variability of NS5B region limited 
the number of sample that could be amplified. Previously identified subtype 1a sample 
could not be amplified from NS5B region, however, 1 subtype 2a and 17 subtype 1b 
samples were amplified and confirmed from NS5B region. There were also 10 
additional samples that were not used in previous study. Their genotypes were 
determined only from NS5B region and all of them were found to be subtype 1b. There 
was 100% concordance between the results of these two methods and they permitted a 
correct characterization of genotypes. 
  
HCV genotypes may have specific or temporal distributions. Therefore, the high 
rate of subtype 1b can be endemic to South Anatolia and Southeast Anatolia regions. To 
determine the predominant genotype in Turkey, genotyping studies with sera collected 
from different regions of Turkey should be performed. 
 
In Europe the prevalence rate of subtype 1b increases from north to south. While 
in Finland the prevalence is 8%, in Sicilian it reaches to 91% (Harrison and Zuckerman, 
1997). The predominancy of subtype 1b in southern Turkey may correlate with the 
general distribution of the subtype 1b in Europe. Lower prevalence rates of other 
genotypes may be explained as the sporadic cases of transmission of genotypes from 
other geographical regions, where endemicity of these genotypes is higher. 
 
 After identification of subtype 1b as the predominant genotype, whole genome 
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sequencing of Turkish HCV-1b isolate from a single human carrier was performed in a 
previous study by Aslı Öztan and whole genome sequence was obtained in this study. 
We compared Turkish HCV-1b isolate with the other variants of subtype 1b at the 
protein level. We identified 37 amino acid changes and 17 of them were found only in 
Turkish HCV-1b isolate. The amount of substitutions was expected as the genotype 1 
shows great similarity with a mean divergence of 29.9% with 1b (Chamberlain et al., 
1997).  
 
To further characterize our isolate, we examined the amino acid sequence at the 
proteolytic cleavage sites and we found high conservation at the amino acid level, 
suggesting no alteration in the processing of the polyprotein. In the ISDR there was 
only one amino acid difference between HCV-BK isolate and Turkish HCV-1b isolate 
and also the amino acid sequence of Turkish isolate was identical to that of HCV J 
isolate at the ISDR. It was reported that HCV-1b isolates with more than 4 amino acid 
difference form HCV-J isolate are related to higher response to interferon treatment 
(Enomoto et al., 1996).  As we found no substitution, we expect to have lower response 
to interferon treatment. Lastly, we investigated the conservation of 26 cysteine residues 
in envelope proteins of Turkish HCV-1b isolate. Cysteine residues are conserved in four 
types of HCV, which is thought to be important for intra- and interchain disulfide bond 
formation. Disulfide bonds may provide the proper folding of E1 and E2 protein 
(Okamoto et al., 1992c). There was no substitution in the cysteine residues and this is a 
promising evidence for proper folding of the E1 and E2 proteins of the Turkish HCV1b.  
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Given the prevalence rate of subtype 1b infections in Turkey is as high as 90%, 
major attention should be given to effects of subtype 1b on diagnosis, disease 
progression, and treatment to develop a suitable health management policy. One of 
important clinical aspect of the subtype 1b infection is the independent association 
between infection with subtype 1b and higher risk of development of liver diseases. If 
we consider the relation of disease duration between disease severity in hepatitis C 
infections, the real outcome of the HCV infections in Turkey in near future is expected 
be more severe, which may be reflected as the increase in the mortality and morbidity 
rate, as the screening of anti HCV antibodies have been performed since 1990.  
 
IFN- α is the only and expensive treatment for hepatitis C infection. The cost per 
year of life saved in non-cirrhotic patients with interferon is $71 950. The response to 
treatment depends on several factors, such as genotype, viremia and age. Therefore, it is 
beneficial to include the predictive variables such as genotype in the cost-benefit 
analyses of HCV treatment to prepare policies to increase the effectivity in management 
of hepatitis C infection. Infection with type 1b is one of the predictive variables 
associated with the low response rate to treatment. In Turkey, most HCV infections are 
caused by type 1b. It would be beneficial to include other variables into account before 
the initiation of therapy to determine likely responders. The type 1b infected patients 
with low viremia level, younger age, without cirrhosis and infected not more than 5 
years are likely to respond to IFN. However, it has been previously reported that 
response of the patients infected with type 1b to IFN may change between countries. To 
design a suitable management policy, the response rate in Turkey should be known as 
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well. There is one preliminary study with 24 patients with HCV infection showed that 
response rate to IFN α-2a is 54 %, which is a promising result and the relapse rate after 
the end of therapy is 30% (Simsek et al., 1996). It is a small-scale study and the 
genotypes of the patients are not known, therefore, there should be more detailed and 
large-scale analysis in Turkey.  As a summary, the cost effective policy for the 
management of HCV infection may include the predictive factors stated above, if we 
consider economy of Turkey.  
 
One of the key issue in hepatitis C infection is the prevention of new cases by 
help of diagnostic tests. Genotype specific sensitivity of the diagnostic tests limits the 
effectiveness of them in detection of infections with genotypes other than type 1. As 
subtype 1b is the predominant genotype in Turkey, screening of anti HCV antibodies in 
blood donations with the diagnostic tests is likely to decrease the number of new cases 
of HCV. This is also related to fact that the major transmission route determined in 
HCV-infected patients with chronic liver disease in Turkey is blood transfusions 
(Cakaloðlu et al., 1992).  There are no cases of vertical transmission determined in 
Turkey and the sexual transmission of HCV is 7.8% (Saltoðlu et al., 1998). 
 
The resistance of HCV-1b to IFN-α and increased risk of development of 
cirrhosis and hepatocellular carcinoma may serious problems in the management of 
chronic hepatitis infection in Turkey. If we add the cost (Davis, 1990) and significant 
side effects (Hoofnagle, 1994) of the IFN therapy, the importance of screening anti 
HCV antibodies becomes more evident.  As the prevalence of the HCV increases with 
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the low socio economic and educational level, it should be considered in designing 
suitable management policy against HCV infection addition to the predominant 
genotype and clinical properties of HCV-1b infection.  However, in efforts to 
development of regional management policies, changes in genotype distribution over 
time should be considered as well. Necessary arrangements should be done after 
genotype determination at time intervals. 
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5. PERSPECTIVES 
 
The results of our study confirmed the previous findings in our laboratory, 
showing the high concordance between both methods. The number of isolates that could 
be amplified from the NS5B region was 29 due to variability of this region. To increase 
this number, our primer pair could be used as outer primer pair and additional internal 
primer pairs can be designed, allowing the amplification of informative region for 
genotyping. 
 
In this study, the sera collected from South Anatolia and Southeast Anatolia 
regions of Turkey was used, to have a better characterization of prevalence of 
genotypes throughout Turkey, a multicentered study might be designed by which sera 
from patients residing in different parts of Turkey can be included in this study.  
 
There is no study to examine the clinical implications of genotypes in Turkey. 
As 91.1 % of the HCV infections are caused by subtype 1b, there could be studies in 
relation to subtype 1b and its effect on interferon (IFN) response. Such a study requires 
a large group of hepatitis C patients from different parts of Turkey, which are clinically 
well defined, that is, age, gender, presence of histological manifestations, co-infection 
with other viruses, viremia levels and genotypes should be known. The study should 
start before interferon treatment and patients should be followed during and after the 
cessation of the therapy to determine the sustained response and long term response as 
well as the relapse rates of the patients. To conclude about the association of subtype 1b 
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infection and response to IFN, multivariate analysis, taking the effect of other variables 
into account in determination the genotypes` effect. The relation of subtype 1b to 
disease progression can be examined by retrospective studies including patients with 
established liver diseases, Frequency of infection due to different genotypes should be 
compared with different stages or outcomes of the disease, such as cirrhosis, HCC to 
determine association. Another way to examine this is to perform prospective studies. 
However, it includes the patients at the onset of the infection and long term follow, so it 
is not an easy task. 
 
Determinants of clinical and biological differences between genotypes might be 
the result of a few nucleotide changes that may not be determined in genotyping from 
subgenomic regions. Addition to this, full length sequence analysis of HCV genome 
will be a future use of studies related to infection, proliferation, and pathogenesis of 
HCV and development of vaccines. In our laboratory, we obtained first full length 
sequence of Turkish HCV isolate. The differences at amino acid sequence level 
between the Turkish isolate and 48 HCV-1b isolates were determined by full length 
sequence alignments. Functional sites, namely proteolytic cleavage sites, ISDR, and 
cysteine residues in E1 and 2 proteins were examined. However, to further characterize 
the Turkish HCV-1b isolate, other regions of the HCV genome should be compared 
with the other isolates at both nucleotide and amino acid sequence levels. One of the 
possible candidate is the NS3 gene, encoding NS3 protein with helicase and protease 
activity. Domains responsible for the helicase and protease activities should be 
examined to detect the presence of any changes in nucleotide or amino acid sequence of 
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this region that might affect the activities of this protein. Another important region of 
HCV is NS5B region encoding the RNA-dependent RNA polymerase of HCV, 
functioning in replication.  
 
Sequence analysis in noncoding regions, 5' UTR and 3' UTR will also be helpful 
in assessing the properties of Turkish HCV-1b isolate. Conserved nucleotide sequences 
in both regions are important sites for the translation (5' UTR) and replication (3' UTR). 
As we obtained partial sequence of these regions, there should be further sequencing of 
these regions and subsequent sequence analysis. 
 
Sequence comparisons and phylogenetic analysis of full length subtype 1b 
sequences can be used to calculate time of divergence of Turkish 1b variants as well as 
it would help to determine genetic relatedness of the Turkish HCV isolates to other 
prototypes from different countries. 
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APPENDIX A: NS5B Sequences  
All NS5B sequences obtained in this study are given in fasta form in 5' → 3' direction. 
>Sample 8 
 
ACATCCGTGTTGAGGAATCAATCTACCAATGTTGTGACTTGGCCCCCGAAGC
CAGACAGGCCATAAGGTCGCTCACAGAGCGGCTCTACATCGGGGGTCCCCT
GACTAATTCAAAAGGGCAGAACTGCGGTTATCGCCGGTGCCGCGCGAGCGG
CGTGCTGACACCACTGCGGCAATACCCTCACATGTTACTTGAAGGCCACTGC
GGCCTGT 
 
>Sample 40 
 
AAATGACATCCGTGTTGAGGAGTCAATTTACCAATGTTGTGACTTGGCCCCC
GAAGCCAGACAGGCTATAAGGTCGCTCACAGAACGGCTTTATATCGGGGGT
CCCCTGACTAACTCAAAAGGGCAGAACTGCGGTTACCGCCGGTGCCGCNCG
ANCGGCGTGCTGACNACTAGCTGCGGCAATACCCTCACATGTTACTTGAAG
GCCTCT 
 
>Sample 41 
 
ACCAATGNTGTGACTTGGCCCCCGAAGCCAGGCAGGCCATAAGGTCGCTGA
CAGAACGGCTTTACATCGGGGGCCCCCTGACTAATTCAAAAGGGCAGAACT
GCGGCTATCGCCGGTGCCGCGCGAGCGGCGTGCTGACAACCAGCTGCGGTA
ATACCCTCACATGTTACTTGAAAGCCTCTGCGGCCTGTCgAGCTGCGAACT 
  
 
>Sample 6O  
 
GGTCACTGAGAATGACATCCGTGTTGAGGAGTCAATtTACCAATGTTGTGAC
TTGGCCCCCGAAGCCAGACAGGCCATAAAGTCGCTCACAGAGCGGCTTTAC
ATCGGGGGCCCCTTGACTAATTCAAAAGGGCAGAACTGTGGCTATCGCCGA
TGCCGCGCGAGCGGCGTGCTGACGACTAGCTGCGGTAATACCCTCACATGTT
ACTTGAAGGCCTC 
 
>Sample 69  
 
AGTCAATTTATCAATGTTGTGACTTGGCCCCCGAAGCCAGNCAGGCTATAAG
GTCGCTCACGGAACGGCTTTACATCGGGGGTCCCCTGACTAACTCAAAAGG
GCAGAACTGCGGTTATCGCCGGTGCCGCGCGAGCGGCGTGCTGACGACTAG
CTGCGGTAATACCCTCACATGNTACTTGAAGGCCTCTGCAGCCTGTCGA 
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>Sample 76  
 
AATGATATCCGTGTTGAGGAGTCGATCTACCAATGTTGTGACTTGGCCCCCG
AAGCCAGACAGGCCATAAGGTCGCTCACAGAGCGGCTTTACATCGGGGGTC
CCCTGACTAATTCAAAAGGGCAGAACTGCGGTTATCGCCGGTGCCGCGCGA
GCGGCGTACTGACGACCACTGCGGTAATACCCTCACATGTTACTTGAAGGCC
TCTGCGGCCTGTC 
 
>Sample 78 
 
CGGTCACTGAGAGTGATATACGTGTTGAGGAGTCAATTTACCAATGTTGTGA
CTTGGCCCCCGAAGCCANACAGGCCATAAGGTCGCTCACAGAGCGGCTTTA
CATCGGGGGTCCCCTGACTAATTCAAAAGGGCAGAACTGTGGTTATCGCCG
GTGCCGCGCGAGCGGTGTGCTGACGACTAGCTGCGGCAATACCCTCACATG
TTACTTGAAGGCCTCTGCGG 
 
>Sample 81 
 
ACGGTCACTGAGAATGACATCCGTGTTGAGGAGTCAATTTACCAATGTTGTG
ACTTGGCCCCCGAAGCCAGGCAGGCTATAAAGTCGCTCACAGAGCGGCTCT
ACATCGGGGGTCCCCTGACTAATTCAAAAGGGCAGAACTGCGGCTATCGCC
GGTGCCGCGCGAGCGGCGTGCTGACGACCAGCTGCGGTAATACCCTTACAT
GTTACTTGAAGGCCTCTGCGGCCTGTCGAc 
 
>Sample 86  
 
AGGAGTCAATTTACCAGTGTTGTGACTTGGCCCCCGAGGCCAGACAGGCCA
TAAGGTCGCTTACAGAGCGGCTTTACATCGGGGGTCCCCTGACTAATTCAAG
GGGGCAGAACTGCGGTTATCGCCGGTGCCGCGCGAGCGGCGTGCTGACGAC
CAGCTGCGGTAATACCCTCACATGTTACTTGAAAGCCTCTGCGGCCTGTCGA
GCTGCAAAGCTCCAGGACTGCACGATGCTCGTGAACGGA 
 
>Sample 87 
 
CANTGTTGTGACTTGGCCCCCGAGGCCAGACAGGCCATAAGGTCGCTTACA
GAGCGGCTTTACATCGGGGGTCCCCTGACTAATTCAAGGGGGCAGAACTGC
GGTTATCGCNGGTGCCGCGCGAGCGGCGTGCTGACGACCAGCTGCGGTAAT
ACCCTCACATGTTACTTGAAAGCCTCTGCGGCCTGTCGAGCTGCAAAGCTCC
AGGACTGCACGATGCTCGTGAA 
 
 
>Sample 94 
 
AATTTACCAATGTTGTGACTTGGCCCCCNAGGCCAGACAGGCCATAAGGTC
GCTCACAGAGCGGCTTTACATGGGGGTCCNCTGACTAATTCAAAAGGGCAN
AACTGCGGTTNTCGCCGGTGCCGCGCAANCGGCGTGCTGACAACTAGCTGC
 99 
GGTAATACCCTACATGCTACTTGAAAGCCTCTGCAGCCTGTCGAGCCGCAAA 
 
>Sample 101 
 
GACATCCGTGTTGAGGAGTCNATTTACCAATGTTGTGACTTGGCCCCCGAGG
CCAGACAGGCCATAAAGTCGCTCACAGAGCGGCTTTACATCGGGGGCCCCC
TGACTAATTCAAAAGGNNNNNNNCTGCGGTTATCGCCGGTGCCGCGCAAGC
GGCGTGCTGACGACTAGCTGCGGTAATACCCTCACATGTTACTTGAAAGCCA
CTGCGGCCTGTCGAGCTGCAAAGCTCCGGGACTG 
 
>Sample 103 
 
ATGTTGTGACTTGGCCCCGAACCAGACAGGCTATAAGGTCGCTCACAGACG
GCTTTACATCGGGGGTCCCCTGTTTAATTCAAAAGGGCAGAACTGCGGTTAT
CGTCGGTGCCGCGCAAGCGGCGTGCTGACAACTAGCTGCGGTAATACCTCA
ATGTTATTGAAGGCCTCTGCGGCCTG 
 
>Sample 114  
 
TCCATATATCAGGCCTGCTCCCTGCCCGAGGAGGCTCGCACTGCCATACACT
CGCTGACTGANANACTTTACGTAGGAGGGCCCATGCTCAACAGCAAGGGCC
ANACCTGCGGATACAGGCGTTGCCGCGCCANCGGATGCTCACCACTAGCAT
GGGAAACACCATTACATGCTACGTAAAACCCTGGCGGCTTGCAAGGCC 
 
>Sample 119 
 
ATTTACCAATGTTGTGACTTGGCCCCCGATGCCAGACAGGCCATAAAGTCGC
TTACAGAGCGGCTTTACATCGGGGGTCCCCTGACTAATTCAAAAGGGCAGA
GCTGCGGTTATCGCCGGTGCCGCGCGAGCGGCGTGCTGACGACTAGCTGTG
GCAATACCCTCACATGTTACTTGAAGGCCTCTGCAGCCTGTCGAGCTGCGAA
GCTCCAGGACTGCACGATGCTCGTGAACGGGGACGACCTTGT 
 
>Sample 131 
 
ACCAATGTTGTGACTTGGCCCCCGAAGCCAGACAGGCCATAAGGTCGCTCA
CAGAGCGGCTTTACATCGGGGGTCCCCTGACTAATTCAAAAGGGCAGAACT
GCGGTTATCGCCGGTGCCGCGCGAGCGGTGTGCTGACGACTAGCTGTGGTA
ATACCCTCACATGTTACTTGAAGGCCTCTGCGGCCTGTCGAGCTGCGAAGCT
CCAGGACTGCACAATGCTCGTGAACGGAGACGACC 
 
>Sample 135  
 
ATTTACCAATGTTGTGACTTGGCCCCCGATGCCAGACAGGCCATAAGGTCGC
TTACAGAGCGGCTTTATATCGGGGGTCCCCTGACTAATTCAAANNNNNNNN
NCTGCGGTTATCGCCGGTGCCGCGCGAGCGGCGTGCTGACGACCAGCTGTG
GCAATACCCTCACATGTTACTTGAAGGCCTCTGCAGCCTGTCGAGCTGCGAA
gCTCCAGGACTG 
 100 
 
>Sample 144  
 
GGTCACTGAGAACGATATCCGTGTTGAGGAGTCAATTTACCAATGTTGTGAC
TTGGCCCCCGAAGCCAGGCAGGCCATAAAGTCGCTCACAGAGCGGCTTTAC
ATCGGGGGTCCCCTGACTAATTCAAAAGGGCAGAACTGCGGCTATCGCCGG
TGCCGCGCGAGCGGCGTACTGACGACCAGCTGCGGTAACACCCTCACATGT
TACTTGAAGGCCACTGCGGC  
 
>Sample 149  
 
CAATGTTGTGACTTGGCCCCCGAAGCCAGACAGGCCATAAGGTCGCTCACA
GAGCGGCTTTATATCGGGGGTCCCCTGACTAATTCAAAAGGGCAGAACTGC
GGTTACCGCCGGTGCCGCGCGAGCGGTGTGCTGACGACTAGCTGCGGCAAT
ACCCTCACATGCTACTTGAAGGCCTCTGCGGCCTGTCGAGCTGCGAAGCTCC
GGGACTGCACAATGCTCGTGAA 
 
>Sample 155 
 
GACTCTATGTGGGCGGCCCCATGTACAACAGCAGGGGAGACTTATGCGGAA
TTCGAAGGTGTCGCGCAAGCGGCGTATTTACCACCAGCTTTGGGAACACACT
GACGTGCTATCTTAAGGCCACCGCAGCTACTAGAGCTGCGGGCCTGAAGAA
CTGCACTATGCTGGTCTGTGGTGACGACTTGGTCGTTATCGCTGAAAGCAGT
GGCGTGGAGGAGGACAAGCGTG 
 
>Sample 160  
 
AATGTTGTGACTTGGCCCCCGAAGCCAGACAGGCCATAAAGTCGCTCACAG
AACGGCTTTACATCGGGGGTCCCCTGACTAACTCAAAAGGGCAGAACTGCG
GTTATCGCCGGTGCCGCGCAAGCGGCGTGCTGACGACTAGCTGCGGTAATA
CCCTCACATGTTACTTGAAGGCCTCTGCGGCCTGTCGAGCTGCAAAGCTCCA
GGACTGCACGATGC 
 
>Sample 167  
 
AATGTTGTGACTTGGCCCCCGAAGCCAGACAGGCTATAAGGTCGCTCACAG
AGCGGCTTTATATCGGGGGTCCCCTGACTAATTCAAAAGGGCAGAACTGCG
GTTATCGTCGGTGCCGCGCAAGCGGTGTGCTTACGACTAGCTGCGGTAATAC
CCTCACATGTTACTTGAAGGCCTCTGCGGCCTGTCGAGCTGCGAAGCTCCAG
GACTGCACAATGCTCGTGAA 
 
 
 
 
>Sample 169  
 
 101 
ACCAATGTTGTGACTTGGCCCCCGAAGCCAGACAGGCCATAAGGTCGCTCA
CAGAGCGGCTTTATATCGGGGGTCCCCTGACTAATTCAAAAGGGCAGAACT
GCGGCTATCGCCGGTGCCGCGCAAGCGGTGTACTCACGACTAGCTGCGGTA
ATACCCTCACATGTTACCTGAAGGCCTCTGCGGCCTGTCGAGCTGCGAAGCT
CCAGGACTGCACAATG 
 
>Sample 170 
 
CAATGTTGTGACTTGGCCCCCGAAGCCAGACAGGCCATAAGGTCGCTCACA
GAGCGGCTTTATATCGGGGGTCCCCTGACTAATTCAAAAGGGCAGAACTGT
GGTTATCGCCGGTGCCGCGCGAGCGGTGTGCTGACGACTAGCTGCGGCAAT
ACCCTCACATGTTACTTGAAGGCCTCTGCGGCCTGTCGAGCTGCGAAGCTCC
AGGACTGCACAATGCT 
 
>Sample 211  
 
AATGTTGTGACTTGGCCCCCGAAGCCAGACAGGCCATAAGGTCGCTCACAG
AGCGGCTTTACATCGGGGGTCCCATGACCAATTCAAAAGGGCAGAACTGCG
GTTATCGCCGGTGCCGCGCGAGCGGCGTACTGACGACTAGCTGCGGTAATA
CCCTTACATGTTACTTGAAAGCCTCTGCGGCCTGTCGAGCTGCGAAGCTCCA
GGACTGC 
 
>Sample 212  
 
ACCAATGTTGTGACTTGGCCCCCGGAAGCCAGACAGGCTATAAGGTCGCTC
ACAGAGCGGCTTTACATCGGGGGTCCCCTGACTAACTCAAAAGGGCAGAAC
TGCGGCTACCGCGGTGCCGCGCAAGCGGCGTGCTGACAACTAGCTGCGGCA
ATACCCTTACATGTTACTTGAAGGCCTCTGCGGCCTGTCGAGCTGCGAAGCT
CCAGGACTGCACGATG 
 
>Sample 213  
 
GATCTATCAATGTTGTGACTTGGCCCCCGAAGCCAGACAGGCTATAAGGTCG
CTCACAGAGCGGCTCTACATCGGGGGTCCTATGACTAATTCAAAAGGGCAG
AACTGTGGTTATCGCCGGTGCCGCGCCAGCGGCGTGCTGACGACTAGCTGC
GGTAATACCCTCACATGTTACTTGAAGGCCTCTGCGGCCTGTCGAGCTGCGA
AGCT 
 
>Sample 215  
 
TCAATTTACCAATGTTGTGACCTGGCCCCCGAAGCCAGACAGGCCATTAAGT
CGCTCACAGAGCGGCTTTACATCGGGGGTCCCTTGACCAATTCAAAAGGGC
AGAACTGCGGTTATCGCCGGTGCCGCGCGAGCGGCGTACTGACGACTAGCT
GCGGTAATACCCTCACATGTTACTTGAAGGCCTCTGCGGCCTGTCGAGCTGC
GAA 
 
>Sample 216  
 102 
 
AATGTTGTGACCTGGCCCCCGAAGCCAGACAGGCCATAAAGTCGCTCACAG
AGCGGCTTTACATCGGGGGTCCCCTGACTAATTCAAAAGGGCAGAGCTGCG
GCTATCGCCGGTGCCGCGCGAGCGGCGTACTGACGACTAGCTGCGGCAATA
CCCTCACATGCTACTTGAAGGCCTCTGCAGCCTGTCGAGCTGCGAAGCTCCA
GGACTGCAC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 103 
APPENDIX B:  Subtype specific consensus sequences. 
 
The subtype specific consensus sequences, used in phylogenic tree construction, are 
given in fasta format in   5' → 3' direction. 
>Consensus Sequence of Subtype 1a (CS 1a) 
 
ATCTACCAgTGTTGTGACCTGGACCCCCAAGCCCGcGTGGCCATcAAGTCCCT
CACcGAGAGgCTTTAtGTcGGgGGcCCtCTTACCAATTCAAgGGGGGAaAACTGC
GGCTAtCGCAGGTGCCGCGCGAgcgGCGTaCTGACaACTAGCTGtGGtAACACC
CTCACtTGcTACATCAAGGCCCaaGCAGCCTGTCGAGCCGCAgGGCTCCgGGAC
TGCACCatgctcgtgtgtggcgacgacttagtcgttatctgtgaaagtcagggagtccaggaggatgcagcgagcctga
gagcc 
 
> Consensus Sequence of Subtype 1b (CS 1b) 
 
ATtTACCAATGtTGTGACtTgGCCCCCGAAGCcAGaCAgGccATAAgGTCGCTCA
CaGAGCGGCTTTAcaTCGGGGGtCCCCTGACcAATTCaAAaGGGCAGAACTGCG
GcTATCGCcGGTGCCGCGCaAgCGGcGTgCTGACGACcAGCTGCGGtAAtACCCT
cACATGTTACtTGAAgGCCtCTGCgGcCTGTCGAGCtGCnAAGCTCcaGGACTGC
ACGatgctngtgnncggagacgacctngtcgtnatctgtganagcgcggga 
 
> Consensus Sequence of Subtype 1c (CS 1c) 
 
ATATAcCAATGTTGTGACCTGCACCCCGACGCACGCGcTGCCATCAAAAATC
TCACTGAGAGATTGTACGTCGGaGGGCCCcTGACcAATTCAAAaGGcGAaAAC
TGCGGCTATCGCAGGTGTCGCGCCAGCGGCGTCCTGACCACcAGCTGCGGTA
ACACTCTCACCTGCTACATCAAGGCCCTAGCAGCCTGTCGAGCCGCAGGGCT
CCaGGACTGCACC                   
 
> Consensus Sequence of Subtype 2a (CS 2a) 
 
ATATAcCAGGCCTGCTCCCTgaCcGAGGAGGCTCGCACTGCCATACACTCGCT
GACTGAGAGaCTNTACGTGGGAGGGCCCATGCTcAAcAGcAAGGGCCAgACC
TGCGGGTACaGGCGtTGCCGcGCCAGCGGgGTGCTcACCACTAGCATGGGaAA
CACCATtACgTGCTAtGTGAAaGCtcTaGCgGCcTGCAAGGCcGCaGgGATAgTtGC
GCCCACa 
 
> Consensus Sequence of Subtype 2b (CS 2b) 
 
ttctcgtatgatacccgctgctttgactcaaccgtcacggagagggacataagaacagaagaatccaTaTATCAGGC
TTGTTCCCTGtCTCAaGAGGCCAGAACTGcCATACACTCGCTC 
ACtGAGAGACTcTACGTAGGAGGGCCCATGACAAACAGCAAAGGgCAgTCCT
GCGGgTACAGGCGTTGCCGCGCAAGCGGCGTtTTCACtACCAGCATGGGGAAc
 104 
ACCATgACaTGtTACaTCAAAGCCcTtGCaGCgTGCAAGGCTGCAGGGATcgTGga
CcctgtcATGcTGGTgTGTGGAGACGACCTgGttGTCATCTcaGAGAGCCAaGGtAat
GAGGAGGACGAGCGAAaCCTGAGAGCtttcacggaggctatgaccaggtattccgcccctcc 
 
>Consensus Sequence of Subtype 2c (CS 2c) 
 
ATCTAcCtGtCcTGtTCACTGCCtgAGGAGGCtCGaACtGCtATACACTCAcTgACTG
AGAGaCTgTACGTaGGgGGGCCCATGACAAACAGCAAaGGgCAaTCCTGCGGg
TACAGGCGTTGCCGCGCGAGCGgaGTGCTCACCACCAGCATGGGtAAcACaCT
cACGTGcTACGTGAAaGCcAaaGCgGCgTGtAACGCCGcGGGCATTGTTGCtcCcA
CC  
 
>Consensus Sequence of Subtype 3a (CS 3a)  
 
cagggtggaagaggagATATACCAATGcTGTaAcCTTGAaCCGGAGGCCAgGAAAGTG
ATcTCCTCCCTCACGGAgCGGCTTTACTGCGGGGGCCCtATGTTcAAcAGcAAG
GGGGCCCAGTGTGGtTATCGCCGtTGCCGTGCcAGtGGAGTTcTGCCTACCAGC
TTcGGcAAcACaATCACTTGTTACATCAAGGCCACaGCGGCtgcgaagGcCGCAGG
CCTCCGGAACCCgGACtttcttgtctgc 
 
>Consensus Sequence of Subtype 4a (CS 4a) 
 
CACtGTaACcGAAAagGACATCAGGgcCGAGGaaGAGgTcTAtCAgTGtTGTGACC
TGGAgcCCGAaGCcCGCAAGGttATtnCtGCCCTCACaGAaAGACTCTAtGTGGGC
GGcCCcATGcAcAACAGCAaGGGaGAcCTtTGtGGGTATCGGAGATGCCGCGCA
AGcGGcGTCTAcACnACcAGCTTCGGgAACACAcTGACGTGCTAtCTcAAAGCcA
CaGCcGCtAtcAgaGCgGCnGGGCTGAgaGACTGCACtATGCTGGTtTGCGGtGACG
ACtTaGTCGTtATCGCtGAgAGcGAcGGCGTgGAgGAGGAtaacCGAGCcCTCC 
 
>Consensus Sequence of Subtype 4d (CS 4d) 
 
CACTGTaACCGAAAGAGACATCAGGGTCGAGGAGGAGGTcTATCAGTGTTGT
GACCTAGAGCCCGAAGCCCGCAAGGTGATATCCGCCCTCACAGAGAGACTC
TAcGTGGGCGGTCCCATGTACAACAGCAaGGGAGACCTTTGCGGaACtCGaCG
gTGCCGCGCAAGCGGCGTATTcACCACCAGCTTTGGGAACACAcTGACGTGC
TATCTTAAGGCCAgCGCAGCCATCAGGGCTGCaGGCCTAAAAGACTGCACCA
TGCTGGTCTGtGGcGACGACTTaGTCGTTATCGCTGAAAGCGaTGGcGTgGAGG
AGGACAAACGtGCCCTCG     
 
> Consensus Sequence of Subtype 4f (CS 4f) 
 
CACAGTGACTGAAAGAGACATCAGGGTCGAGGAAGAGGTCTAcCAGTGtTGc
GAcCTGGAGCCTGAAaCCCGCAAggTaATATCCGCCCTcACTGAaAGACTCTAc
GTGGGCGGtCCcATGcAcAACAGCAGAGGAGACCTgTGCGGGTAcCGTAGATG
CCGCGCGAGCGGcGTgTACACcGGcCTaAaGGACTGCACtATGTTgGTGaaCGGT
GAcGACtTaGTCGTTATCGCcGAaAGCGATGGcGTCGAcGAgGACCGcCGAGCC
CTCG                             
 105 
 
>Consensus Sequence of Subtype 4h (CS 4h) 
 
CACGGTGACTGAAAGGGACATCaGGGTCGAGGAAGAGATCTAcCAGTGCTGT
GACCTGGAGCCCGAGGCaCGCAAGGTaATATCCGCCCTCACAGAAAGaCTCT
AcAAGGGCGGCCCCATGTATAACAGCAAGGGGGACCTATGcGGGcaTCGGAG
aTGCCGCGCAAGCGGGGTaTACACCACaAGCTTCGGaAACACAGTAACGTGCT
ACCTcAAaGCCACGGCAGCCACCAGGGCTGCaGGGCTGAAGGATTGCACcAT
GCTGGTATGCGGTGACGACcTaGTCGTTATCGCcGAAAGCaGTGGcGTGGAGG
AGGAcacCCGAGCCCTcC                                                    
 
>Consensus Sequence of Subtype 5a (CS 5a) 
 
ATtTACCAATCATGTGACTTgCAGCCtGAGGcgCGcGtGGCAATACGGTCACTC
ACCCAACGCCTGTACTGTGGAGGCCCtATGTATAACAGCAAGGGGCAACAAT
gtggTTAtCGTAGATGCCGCGCcAGCGGCGTCTTCACCACtAGTATGGGCAACA
CCATGACGTGCTAcATcAAGGCTttaGCCtCCTGTAGAGCtGCAAAGCTCCaGGA
cTGCACG     
 
>Consensus Sequence of Subtype 6a (CS 6a) 
 
ATcTATCAGTCTTGCCAGCTgGATCCCGTAGCAAGGAGGGCAGTATCATCCC
TGACAGAACGGCTCTACGTAGGCGGCCCCATGGTGAACTCCAAgGGACAGT
CATGTGGCTAcCGTAGATGCCGcGCCAGTgGGTGCTGCCCAcGAGCATGGGA
AAcACCATCACGtGcTATCTGAAGGCAcACGCCTGCAGGGCGGCCAACATCAa
GGACTGTGAc                                      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
